

	Ref #	Hits	Search Text
1	S1	1	("20070042950").PN.
2	S2	5	((("7026281") or ("6057422") or ("5792747") or ("5416073") or ("6380358"))).PN.
3	S3	0	Achally-andrew-v.in.
4	S4	44	schally-andrew-v.in.
5	S5	24	varga-jozsef.in.
6	S6	9	zarandi-marta.in.
7	S7	10	cai-ren-zhi.in.
8	S8	1475	GhRH
9	S9	9	GhRH and "His.sup.9"
10	S10	0	GhRH same "His.sup.9"

## INVENTOR SEARCH

=> fil capl  
 FILE 'CAPLUS' ENTERED AT 12:18:46 ON 20 SEP 2007  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Sep 2007 VOL 147 ISS 13  
 FILE LAST UPDATED: 19 Sep 2007 (20070919/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>  
 'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> => d que 119  
 L1 1 SEA FILE=CAPLUS ABB=ON US2006-566776/AP  
 L2 1256 SEA FILE=CAPLUS ABB=ON SCRALLY A7/AU  
 L3 840 SEA FILE=CAPLUS ABB=ON VARGA J7/AU  
 L4 101 SEA FILE=CAPLUS ABB=ON ZARANDI M7/AU  
 L5 1127 SEA FILE=CAPLUS ABB=ON CAI R7/AU  
 L9 227 SEA FILE=REGISTRY ABB=ON [YH][R'CIT'DA[IV][FY'NAL'JT[N'CIT'OS  
 TA'ABU''AIB']...[K'ORN''HAR''CIT''NLE'A]VL[GA'ABU''AIB''NLE'Q'C  
 IT'H][QR]JS[A'ABU']][HR'CIT']][K'ORN''CIT']][LA'AIB']LQDI[ML'NLE''  
 ABU'R']][R'HAR'SNDA'ABU''CIT']]/SQSP  
 L14 73 SEA FILE=CAPLUS ABB=ON L9  
 L19 3 SEA FILE=CAPLUS ABB=ON (L1 AND L14) OR (L2 AND L3 AND L4 AND L5 AND L14)

=> d ibib abs hitseq 119 1-3

L19 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS ON STN  
 ACCESSION NUMBER: 2005:1208697 CAPLUS Full-text  
 DOCUMENT NUMBER: 144:246654  
 TITLE:  
 Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone is linked to PKC, MAPK and c-jun intracellular signalling  
 Stangelberger, Anton; Schally, Andrew V.; Varga, Jozsef L.; Zarandi, Marta; Cai, Ren-Zhi; Baker, Benjamin; Hamman, Brian D.; Armatas, Patricia; Kanashiro, Celia A. Veterans Affairs Medical Center, Polypeptide and Cancer Institute, New Orleans, LA, 70112-1262, USA  
 European Journal of Cancer (2005), 41(17), 2735-2744  
 CODEN: EJCAEL; ISSN: 0959-8049

## CORPORATE SOURCE:

## SOURCE:

PUBLISHER: Elsevier Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Bombesin/gastrin-releasing peptide (BN/GRP) antagonists RC-3940-11 and RC-3940-Et, and growth hormone-releasing hormone (GHRH) antagonists MZ-J-7-118 and RC-J-29-18 inhibit the growth of human androgen-independent PC-3 and DU-145 prostate cancers in nude mice. Additive inhibitory effects were observed after treatment with both classes of analogs. In the present study, we investigated the effects of these antagonists on intracellular signaling pathways of protein kinase C (PKC), mitogen activated protein kinases (MAPK) and c-fos and c-jun oncogenes that are involved in tumor cell proliferation. In PC-3 tumors, antagonists of BN/GRP and GHRH decreased significantly the expression of PKC isoforms alpha (α), eta (η) and zeta (ζ) and increased that of delta (δ) PKC protein. MAPK was not detectable. In DU-145 tumors, which constitutively express MAPK, all treatments strongly decreased the levels of p42/44 MAPK. Treatment with the antagonists tended to reduce m-RNA for c-jun in both tumor models. In proliferation assays in vitro, inhibitors of PKC and MAPK diminished growth of DU-145 and PC-3 cells. These findings suggest that antagonists of BN/GRP and GHRH inhibit the growth of androgen-independent prostate cancer by affecting intracellular signaling mechanisms of PKC, MAPK and c-jun.

IT 845715-95-9, MZ-J-7-118

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GHRH antagonist MZ-J-7-118 down-regulated expression of PKC, MAPK, c-jun mRNA involved in intracellular signaling there by inhibited tumor cell proliferation in human PC-3 and DU-145 prostate cancer cell line carrying mouse models)

RN 845715-95-9 CAPLUS

CN L-Lysineamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHYQVLXQLSAR KLQDIYRX

IT 845716-11-2, RC-J-29-18

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GHRH antagonist RC-J-29-18 down-regulated expression of PKC, MAPK, c-jun mRNA involved in intracellular signaling there by inhibited tumor cell proliferation in human PC-3 and DU-145 prostate cancer cell line carrying mouse models)

RN 845716-11-2 CAPLUS

CN L-Lysineamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

REFERENCE COUNT: 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2005-810564 CAPLUS Full-text  
DOCUMENT NUMBER: 143:39123  
TITLE:

Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human

AUTHOR(S): Stangelberger, Anton; Schally, Andrew V.; Varga, Jozsef L.; Hammann, Brian D.; Groot, Kate; Halmos, Gabor; Cai, Ren-Zhi; Zarandi, Marta

CORPORATE SOURCE: Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, New Orleans, LA, USA  
SOURCE: Prostate (Hoboken, NJ, United States) (2005), 64(3), 303-315

CODEN: PRSTDS; ISSN: 0270-4137  
PUBLISHER: Wiley-Liss, Inc.

DOCUMENT TYPE: English  
LANGUAGE: Journal

AB Antagonists of growth hormone releasing hormone (GHRH) as well as antagonists of bombesin/gastrin releasing peptide (BN/GRP) inhibit the growth of various malignancies (cancers) including prostate cancer. We investigated the effects of GHRH antagonists MZ-J-7-118 and RC-J-29-18, BN/GRP antagonists RC-3940-II and RC-3940-III and the combination of MZ-J-7-118 and RC-3940-II on the growth of PC-3 and DU-145 human androgen independent prostate cancers xenografted s.c. into nude mice. To elucidate the mechanisms of action of these analogs, growth factors like IGF-II (insulin-like growth factor-II), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and epidermal growth factor receptor/human epidermal growth factor receptor (EGF-R/HER) family were measured in tumors as well as IGF-I in serum. Antagonists of GHRH and BN/GRP alone or in combination significantly inhibited growth of PC-3 and DU-145 tumors, the greatest inhibition of tumor volume being achieved by combination of MZ-J-7-118 (5 ng/day) and RC-3940-II (10 µg/day). BN/GRP and GHRH antagonists and their combination also decreased the expression of VEGF significantly in PC-3 and non-significantly in DU-145, as measured by RTA for VEGF protein and RT-PCR for mRNA levels of VEGF. GHRH and BN/GRP antagonists reduced bFGF concns. and the maximal binding capacity of EGF receptors, and their mRNA levels in PC-3 and DU-145 tumors. mRNA levels for HER-2 and -3 were also diminished in PC-3 tumors by GHRH and BN/GRP antagonists. No changes in HER-4 were found after treatment. Serum IGF-I and tumoral IGF-II levels were not affected by the analogs. BN/GRP and GHRH antagonists inhibit growth of PC-3 and DU-145 prostate cancers by suppressing the expression of tumoral growth factors such as VEGF and bFGF as well as the receptors for EGF and related HER-2 and -3. Additive effects on tumor inhibition (TI) in vivo, but not on VEGF, bFGF, or members of the EGF/HER receptor family, can be achieved by the joint administration of both classes of analogs.

IT 845715-95-3, MZ-J-7-118  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GHRH antagonist MZ-J-7-118 alone or in combination with RC-3940-II markedly inhibited tumor growth by suppressing expression of VEGF, bFGF, receptors of EGF/HER family in PC-3, DU-14 human

androgen-independent prostate cancer in nude mouse)  
RN 845715-95-9 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

IT 845716-11-2, RC-J 29-18

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GHRH antagonist RC-J-29-18 alone or in combination significantly inhibited tumor growth by suppressing expression of VEGF, bFGF and receptors of EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancer into nude mouse)

RN 845716-11-2 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:158688 CAPLUS Full-text

DOCUMENT NUMBER: 142:261790

TITLE: Preparation of analogs of human growth hormone releasing hormone hGH-RH(1-29)NH2 having antagonistic activity for hGH-RH

INVENTOR(S): Schally, Andrew V.; Varga, Jozsef; Zarandi, Marta; Cai, Ren Zhi

PATENT ASSIGNEE(S): The Administrators of the Tulane Educational Fund, USA  
SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXDZ

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016953	A2	20050224	WO 2004-US24183	20040726
WO 2005016953	A3	20060209		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GM, GR, HR, HU, ID, IL, IN, IS, JP, KE, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, US, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, GH, GM, KE, LS, MM, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, MO, TJ, TM, AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TD, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2004265280 A1 20050224 AU 2004-265280 20040726  
 CA 2534436 A1 20050224 CA 2004-2534436 20040726  
 EP 1651662 A2 20060503 EP 2004-757325 20040726  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR  
 BR 2004013257 A 20061129 BR 2004-13257 20040726  
 CN 1871020 A 20061129 CN 2004-8002286 20040726  
 IN 2006KN00445 A 20070706 IN 2006-KN445 20060227  
 NO 2006001060 A 20060503 NO 2006-1060 20060303  
 US 2007042950 A1 20070222 US 2006-566776 20061002 <--  
 US 2003-492706P P 20030805  
 WO 2004-492706P W 20040726  
 WO 2004-492706P W 20040726  
 PRIORITY APPL. INFO.:  
 OTHER SOURCE(S):  
 AB MARPAT 142:261790

AB The invention relates to novel synthetic antagonistic analogs of hGH-RH(1-29)NH<sub>2</sub> which inhibit the activity of endogenous hGH-RH on the pituitary GH-RH receptors and inhibit the proliferation of human cancers. The higher inhibitory potencies of the new analogs, as compared to previously described ones, results from replacement of various amino acids. Peptides R1-A0-A1-A2-Leu-Gln-Asp-Ile-A28-A29-A30-R2 (R1 is phenylacetyl, hydrocinamoyl, des-amino-tyrosyl, indole-3-acetyl or -propionyl, 1- or 2-naphthylacetyl, 2-naphthylpropionyl, isobutyryl, Me(CH<sub>2</sub>)<sub>2</sub>-2-OCOC or HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>-2-OCOC or any other aliphatic carboxyl group of 2-30 carbon atoms and any carbocyclic or heterocyclic aromatic carboxyl group of 3-8 carbon atoms containing at least one atom S, N and O in the heterocyclic ring; A0-A30 are amino residues (defined for each A); A0 may also be a C-N single bond and A30 may also be a C-N or C-O single bond; R2 is NH<sub>2</sub>, NHH<sub>2</sub>, NHOH, NHR<sub>3</sub>, NR<sub>3</sub>R<sub>4</sub>, OH or -OR<sub>3</sub>, where R<sub>3</sub> and R<sub>4</sub> are alkyl, alkenyl, alkynyl, phenylalkyl, Ph or CHPh<sub>2</sub> (with provisos) or their pharmaceutically acceptable salts are claimed. Thus, [HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>CO-Tyr<sup>1</sup>, D-Arg<sup>2</sup>, Phe<sup>3</sup>(C1)6, Arg<sup>9</sup>, Abu<sup>15</sup>, Nle<sup>27</sup>, D-Arg<sup>28</sup>, Har<sup>29</sup>]hGH-RH(1-29)NH<sub>2</sub> (Har is homocarginine), prepared by the solid-phase method, showed a much increased and protracted inhibitory effect on GH-RH-elicited GH release in vitro (compared to the standard antagonist) and a substantial increase in binding affinity to the GH-RH receptor isoforms on PC-3 tumor membranes (compared to the binding affinity of reference compds.).

IT 845715-10-8P 845715-11-9P 845715-12-0P  
 845715-13-1P 845715-14-2P 845715-15-3P  
 845715-16-4P 845715-17-5P 845715-18-6P  
 845715-19-7P 845715-20-8P 845715-21-1P  
 845715-22-2P 845715-23-3P 845715-24-4P  
 845715-25-5P 845715-26-6P 845715-27-7P  
 845715-28-8P 845715-29-9P 845715-30-2P  
 845715-31-3P 845715-32-4P 845715-33-5P  
 845715-34-6P 845715-35-7P 845715-36-8P  
 845715-37-9P 845715-38-0P 845715-39-1P  
 845715-40-4P 845715-41-5P 845715-42-6P  
 845715-43-7P 845715-44-8P 845715-45-9P  
 845715-46-0P 845715-47-1P 845715-52-8P  
 845715-53-9P 845715-54-0P 845715-55-1P

845715-56-2P 845715-57-3P 845715-58-4P  
 845715-59-5P 845715-62-0P 845715-63-1P  
 845715-72-2P 845715-73-3P 845715-74-4P  
 845715-75-5P 845715-76-6P 845715-77-7P  
 845715-78-8P 845715-79-9P 845715-80-2P  
 845715-81-3P 845715-82-4P 845715-83-5P  
 845715-84-6P 845715-85-7P 845715-86-8P  
 845715-87-9P 845715-88-0P 845715-89-1P  
 845715-90-4P 845715-91-5P 845715-92-6P  
 845715-93-7P 845715-94-8P 845715-95-9P  
 845715-96-0P 845715-97-1P 845715-98-2P  
 845715-99-3P 845716-00-9P 845716-01-0P  
 845716-02-1P 845716-03-2P 845716-05-4P  
 845716-06-5P 845716-07-6P 845716-08-7P  
 845716-09-8P 845716-10-1P 845716-11-2P  
 845716-12-3P 845716-13-4P 845716-14-5P  
 845716-15-6P 845716-16-7P 845716-17-8P  
 845716-18-9P 845716-19-0P 845716-20-3P  
 845716-21-4P 845716-22-5P 845716-23-6P  
 845716-24-7P 845716-25-8P 845716-26-9P  
 845716-27-0P 845716-28-1P 845716-29-2P  
 845716-30-5P 845716-31-6P 845716-32-7P  
 845716-33-8P 845716-34-9P 845716-35-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Preparation of analogs of human growth hormone releasing hormone hGH-RH(1-29)NH<sub>2</sub> having antagonistic activity for hGH-RH)  
 RN 845715-10-8 CAPLUS  
 CN L-Lysanamide, N-(1-oxohexyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFITNRY RKVLXQLSAR KLIQDIXRX

RN 845715-11-9 CAPLUS

CN L-Lysanamide, N-(5-carboxy-1-oxopentyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFITNRY RKVLXQLSAR KLIQDIXRX

RN 845715-12-0 CAPLUS

CN L-Lysanamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-

arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-13-1 CAPLUS

CN L-Lysinamide, N-(7-carboxy-1-oxoheptyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-arginyl-L-tyrosyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-14-2 CAPLUS

CN L-Lysinamide, N-(1-oxododecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-tyrosyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-15-3 CAPLUS

CN L-Lysinamide, N-(9-carboxy-1-oxononyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-arginyl-L-tyrosyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-16-4 CAPLUS

CN L-Lysinamide, N-(1-oxododecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-

(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-17-5 CAPLUS

CN L-Lysinamide, N-(11-carboxy-1-oxoundecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-arginyl-L-tyrosyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-18-6 CAPLUS

CN L-Lysinamide, N-(1-oxotetradecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-19-7 CAPLUS

CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-arginyl-L-tyrosyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-20-0 CAPLUS

CN L-Lysinamide, N-(1-oxohexadecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-21-1 CAPLUS  
CN L-Lysinamide, N-(15-carboxy-1-oxopentadecyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-alanyl-L-arginyl-L-tyrosyl-L-arginyl-N6-(aminoininomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-22-2 CAPLUS  
CN D-Argininamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-tyrosyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-N6-(aminoininomethyl)-L-lysyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-23-3 CAPLUS  
CN D-Argininamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-tyrosyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-N6-(aminoininomethyl)-L-lysyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-24-4 CAPLUS  
CN L-Lysinamide, N-(1-oxohexadecyl)-L-phenylalanyl-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoininomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 FYRDAIFTNR YRKVLXQLSA RKLQDIXRX

RN 845715-25-5 CAPLUS  
CN L-Lysinamide, N-(1-oxohexadecyl)-D-phenylalanyl-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoininomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 FYRDAIFTNR YRKVLXQLSA RKLQDIXRX

RN 845715-26-6 CAPLUS  
CN L-Lysinamide, N2-(phenylacetyl)-L-arginyl-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoininomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 RYRDAIFTNR YRKVLXQLSA RKLQDIXRX

RN 845715-27-7 CAPLUS  
CN L-Lysinamide, N2-(phenylacetyl)-D-arginyl-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoininomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 RYRDAIFTNR YRKVLXQLSA RKLQDIXRX

RN 845715-28-8 CAPLUS  
CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-N5-(aminocarbonyl)-L-ornithyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoininomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-29-9 CAPLUS



10/566776

N6-(aminoiminomethyl)-L-lysyl-4-(aminoiminomethyl)-L-phenylalanyl-L-arganyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-38-0 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-L-arganyl-L-histidyl-L-arganyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRH RKVLXQLSAR KLLQDIXRX

RN 845715-39-1 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-L-arganyl-3-cyclohexyl-L-alanyl-L-arganyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRX RKVLXQLSAR KLLQDIXRX

RN 845715-40-4 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-(aminoiminomethyl)-L-lysyl-(3S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carbonyl-L-arganyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-41-5 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-(aminoiminomethyl)-L-lysyl-3-(2-naphthalenyl)-L-alanyl-L-arganyl-L-lysyl-L-

13

10/566776

valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-42-6 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-(aminoiminomethyl)-L-lysyl- $\beta$ -phenyl-L-phenylalanyl-L-arganyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-43-7 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-(aminoiminomethyl)-L-lysyl-4-amino-L-phenylalanyl-L-arganyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-44-8 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-(aminoiminomethyl)-L-lysyl-L-tryptophyl-L-arganyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-leucyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-45-9 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-(aminoiminomethyl)-L-lysyl-4-nitro-L-phenylalanyl-L-arganyl-L-lysyl-L-

14

valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-46-0 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-N6- (aminoiminomethyl)-L-lysyl-3-(3-pyridinyl)-L-alanyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-47-1 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-N6- (aminoiminomethyl)-L-lysyl-O-ethyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-52-8 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-histidyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-L-tyrosyl-L-threonyl-L-asparagyl-N6- (aminoiminomethyl)-L-lysyl-4-benzoyl-L-phenylalanyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-53-9 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-L-

arginyl-L-tyrosyl-L-arginyl-N6- (aminoiminomethyl)-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-54-0 CAPLUS

CN L-Lysinamide, N-(1-oxo-3-phenylpropyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-N6- (aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-55-1 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-N6- (aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-56-2 CAPLUS

CN L-Lysinamide, N-(1-oxo-3-phenylpropyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXX RKVLXQLSAR KLLQDIXRX

RN 845715-57-3 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-

L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 845715-58-4 CAPLUS

L-lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-  
 alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-theonyl-L-asparaginy-L-N6-  
 (aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-  
 leucyl-2-methylalanyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-  
 lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-  
 norleucyl-D-arginyl-N6-(aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY R KVLXQLSAR KLLQDIXRX

RN 845715-59-5 CAPLUS

CN L-lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-D-phenylalanyl-L-threonyl-L-asparaglyl-N6-(aminoiminomethyl)-L-lyso-L-methyl-L-tyrosyl-L-arginyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysoyl-L-leucyl-L-glutamyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-N-ethyl- (9CI) INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY RXVLXQLSAR KLLQDIXRX

RN 845715-62-0 CAPLUS

L-lysineamide, N-(1-oxo-3-phenylpropyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaglyl-N<sub>6</sub>-(aminoiminomethyl)-L-lysyl-L-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -L-lysyl-L-isoleucyl-L-norleucyl-D-leucyl-N<sub>6</sub>-(aminoiminomethyl)-L-lysyl-L-aspartyl-L-isoleucyl-L-norleucyl-D-leucyl-N<sub>6</sub>-(aminoiminomethyl)-L-lysyl-N<sub>6</sub>-(aminoiminomethyl)-L-<sup>9C1</sup> (JCA INDEX NAME)

NTE modified (modifications unspecified)

1 YRDAIFTNXY RVLXOLSAR KLLQDIXRXX  
SEO

RN 845715-63-1 CAPLUS

L-lysineamide, N-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-tyrosyl-D-arginyl-L-  
 L-lysineamide, N-[3-(4-hydroxyphenyl)-1-oxopropyl]-L-tyrosyl-D-arginyl-L-  
 α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-  
 asparaginyl-N6-(aminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-  
 lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-

L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arganyl-N<sup>6</sup>-(aminoiminomethyl)-L-lysyl-N<sup>6</sup>-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ I YRDAIFTNXY RKVLXQLSAR KLLQDIXRXX

RN 845715-72-2 CAPLUS

CN L-Lysinamide, N-(3-(1H-indol-3-yl)-1-oxypropyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaglyl-N6-(aminoiminomethyl)-L-hydroxy-O-methyl-L-tyrosyl-L-arginyll-L-lysyl-L-valyl-L-leucyl-(ZS)-2-aminoisobutyryl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyll-L-lysyl-L-leucyl-L-leucyl-L-glutaminyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-L-lysyl-N6-(aminoiminomethyl)-(9CI) (CA INDEX NAME)

RN	845715-73-3	CAPLUS
CN	<p>L-lysineamide, N-(1-oxo-3-phenylpropyl)-L-tyrosyl-D-arginyl-L-<math>\alpha</math>-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-N<sup>6</sup>-(aminomino)methyl-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arganyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-<math>\alpha</math>-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N<sup>6</sup>-(aminomino)methyl)-L-lysyl-N<sup>6</sup>-(aminomino)methyl)- (9CI) (CA INDEX NAME)</p>	

RN	845715-74-4	CAPLUS
CN	L-lysineamide, N-(1-oxo-3-phenylpropyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaglyl-N <sub>6</sub> -(aminoiminomethyl)-L-lysylo-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-argeryl-L-lysylo-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-argeryl-D-arginyl-N <sub>6</sub> -(aminoiminomethyl)-(9CI) (CA INDEX NAME)	

.....

RN	845715-75-5	CAPLUS
CN	D-Arginamide, N-(1-oxo-3-phenylpropyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartatyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparatyl-N6-(aminoimino)ethyl-L-lysyl-O-methyl-L-tyrosyl-L-arginy-L-	

lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-L-lysyl-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY RKVLXQLSAR KLLQDIXRX

RN 845715-76-6 CAPLUS

CN L-Lysinamide, N-(1-oxo-3-phenylpropyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6- (aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-(4-((aminoiminomethyl)aminobutyl))- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY RKVLXQLSAR KLLQDIXRX

RN 845715-77-7 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6- (aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-(4-((aminoiminomethyl)aminobutyl))- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY RKVLXQLSAR KLLQDIXRX

RN 845715-78-8 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6- (aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY HKVLXQLSAR KLLQDIXRX

RN 845715-79-9 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-

(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-N6- (aminoiminomethyl)-L-lysyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY XKVLXQLSAR KLLQDIXRX

RN 845715-80-2 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6- (aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-4- (aminoiminomethyl)-L-phenylalanyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY FKVLXQLSAR KLLQDIXRX

RN 845715-81-3 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6- (aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-N5- (aminocarbonyl)-L-ornithyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY XKVLXQLSAR KLLQDIXRX

RN 845715-82-4 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-4- (aminoiminomethyl)-L-phenylalanyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY RKVLXQLSAR KLLQDIXRX

RN 845715-83-5 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-

alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-4-  
(aminoiminomethyl)-L-phenylalanyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-  
leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-  
arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-glutamyl-L- $\alpha$ -aspartyl-L-  
isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX  
NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNHY RKVLXQLSAR KLLQDIXRX

RN 845715-84-6 CAPLUS  
CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-  
alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-4-  
histidyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-  
aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-  
leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-  
arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNHY RKVLXQLSAR KLLQDIXRX

RN 845715-85-7 CAPLUS  
CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-  
alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-4-  
(aminoiminomethyl)-L-phenylalanyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-  
valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-  
L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-  
isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX  
NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNHY RKVLXQLSAR KLLQDIXRX

RN 845715-86-8 CAPLUS  
CN L-Lysinamide, N-(9-carboxy-1-oxononyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -  
aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-  
asparaginy-4-(aminoiminomethyl)-L-phenylalanyl-O-methyl-L-tyrosyl-L-  
arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-  
leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-  
 $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-  
(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNHY RKVLXQLSAR KLLQDIXRX

RN 845715-87-9 CAPLUS  
CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -

aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-  
asparaginy-4-(aminoiminomethyl)-L-phenylalanyl-O-methyl-L-tyrosyl-L-  
arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-  
leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-  
 $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-  
(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNHY RKVLXQLSAR KLLQDIXRX

RN 845715-88-0 CAPLUS  
CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-  
alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-4-  
(aminoiminomethyl)-L-phenylalanyl-O-methyl-L-tyrosyl-L-histidyl-L-lysyl-L-  
valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-  
L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-  
isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX  
NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNHY HKVLXQLSAR KLLQDIXRX

RN 845715-89-1 CAPLUS  
CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-  
alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-N5-(aminocarbonyl)-L-  
ornithyl-4-(aminoiminomethyl)-L-phenylalanyl-O-methyl-L-tyrosyl-L-histidyl-  
L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-  
seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -  
aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI)  
(CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNHY HKVLXQLSAR KLLQDIXRX

RN 845715-90-4 CAPLUS  
CN L-Lysinamide, N-(1-naphthalenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -  
aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-N5-  
(aminocarbonyl)-L-ornithyl-4-(aminoiminomethyl)-L-phenylalanyl-O-methyl-L-  
tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-  
glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-  
glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-  
(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNHY HKVLXQLSAR KLLQDIXRX

RN 845715-91-5 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-N5-(aminocarbonyl)-L-ornithyl-4-(aminoiminomethyl)-L-phenylalanyl-O-methyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-tyrosyl-L-lysyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTXFY HKVLXQLSAR KLLQDIXRX

RN 845715-92-6 CAPLUS

CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-N5-(aminocarbonyl)-L-ornithyl-4-(aminoiminomethyl)-L-phenylalanyl-O-methyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTXFY HKVLXQLSAR KLLQDIXRX

RN 845715-93-7 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-N5-(aminocarbonyl)-L-ornithyl-4-(aminoiminomethyl)-L-phenylalanyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTXFY HKVLXQLSAR KLLQDIXRX

RN 845715-94-8 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-N5-(aminocarbonyl)-L-ornithyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTXHY HKVLXQLSAR KLLQDIXRX

RN 845715-95-9 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

RN 845715-96-0 CAPLUS

CN L-Lysinamide, N-(9-carboxy-1-oxononyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

RN 845715-97-1 CAPLUS

CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

RN 845715-98-2 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminy-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTXNY RKVLXQLSAH KLLQDIXRX

RN 845715-99-3 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-

(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY HKVLXQLSAH KLLQDIXRX

RN 845716-00-9 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY HKVLXQLSAH KLLQDIXRX

RN 845716-01-0 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY HKVLXQLSAH KLLQDIXRX

RN 845716-02-1 CAPLUS

CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY HKVLXQLSAH KLLQDIXRX

RN 845716-03-2 CAPLUS

CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-

valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY HKVLXQLSAH KLLQDIXRX

RN 845716-05-4 CAPLUS

CN L-Lysinamide, N-(1-naphthalenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY HKVLXQLSAH KLLQDIXRX

RN 845716-06-5 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY HKVLXQLSAH KLLQDIXRX

RN 845716-07-6 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-N5-(aminocarbonyl)-L-ornithyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY HKVLXQLSAH KLLQDIXRX

RN 845716-08-7 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-lysyl-L-valyl-L-leucyl-L-histidyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-

(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

RN 845716-09-8 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HXVLXQLSAR XLLQDIXRX

RN 845716-10-1 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HXVLXQLSAR XLLQDIXRX

RN 845716-11-2 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-seryl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

RN 845716-12-3 CAPLUS

CN L-Lysinamide, N-(1-oxodecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-seryl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

RN 845716-13-4 CAPLUS

CN L-Lysinamide, N-(1-oxododecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-seryl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

RN 845716-14-5 CAPLUS

CN L-Lysinamide, N-(1-oxo-3-phenylpropyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-seryl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

RN 845716-15-6 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-seryl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-methyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HKVLXQLSAR KLLQDIXRX

RN 845716-16-7 CAPLUS

CN L-Lysinamide, N-(13-carboxyl-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-seryl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-leucyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HXVLXQLSAR XLLQDIXRX

RN 845716-17-8 CAPLUS  
CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-O-ethyl-L-tyrosyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-glutamyl-L-leucyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFY HXVLXQLSAH XLLQDIXRX

RN 845716-18-9 CAPLUS  
CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-β-phenyl-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFH HXVLXQLSAH XLLQDIXRX

RN 845716-19-0 CAPLUS  
CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-4-nitro-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFH HXVLXQLSAH XLLQDIXRX

RN 845716-20-3 CAPLUS  
CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFH HXVLXQLSAH XLLQDIXRX

RN 845716-21-4 CAPLUS  
CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-O-ethyl-L-tyrosyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFY HXVLXQLSAH XLLQDIXRX

RN 845716-22-5 CAPLUS  
CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-β-phenyl-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFH HXVLXQLSAH XLLQDIXRX

RN 845716-23-6 CAPLUS  
CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-4-nitro-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFH HXVLXQLSAH XLLQDIXRX

RN 845716-24-7 CAPLUS  
CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFH HXVLXQLSAH XLLQDIXRX

RN 845716-25-8 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-β-phenyl-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAF HXVLXQLSAH XLLQDIXRX

RN 845716-26-9 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-4-nitro-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAF HXVLXQLSAH XLLQDIXRX

RN 845716-27-0 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-O-ethyl-L-tyrosyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAF HXVLXQLSAH XLLQDIXRX

RN 845716-28-1 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-β-phenyl-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAF HXVLXQLSAH XLLQDIXRX

RN 845716-29-2 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-4-nitro-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAF HXVLXQLSAH XLLQDIXRX

RN 845716-30-5 CAPLUS

CN L-Lysinamide, N-(13-carboxyl-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4- (aminoiminomethyl)-L-phenylalanyl-β-phenyl-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAF HXVLXQLSAH XLLQDIXRX

RN 845716-31-6 CAPLUS

CN L-Lysinamide, N-(13-carboxyl-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4- (aminoiminomethyl)-L-phenylalanyl-4-nitro-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAF HXVLXQLSAH XLLQDIXRX

RN 845716-32-7 CAPLUS

CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4- (aminoiminomethyl)-L-phenylalanyl-β-phenyl-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6- (aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAF HXVLXQLSAH XLLQDIXRX

RN 845716-33-8 CAPIUS  
CN L-Lysinamide, N-(1-oxoethyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-4-nitro-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFF HXVLXQLSAH XLLQDIXRX

RN 845716-34-9 CAPIUS  
CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-β-phenyl-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFF HXVLXQLSAH XLLQDIXRX

RN 845716-35-0 CAPIUS  
CN L-Lysinamide, N-(13-carboxy-1-oxotridecyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-4-(aminoiminomethyl)-L-phenylalanyl-4-nitro-L-phenylalanyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)-N-ethyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAFF HXVLXQLSAH XLLQDIXRX

# PEPTIDE 96

=> fil reg; d que lll  
FILE 'REGISTRY' ENTERED AT 12:21:40 ON 20 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3  
DICTIONARY FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

LL1 5 SEA FILE=REGISTRY ABB=ON YRDA[IV]FTAHYH'ORN'VL'ABU'[QR]LS[A'AB  
U']H'ORN'[LA'AIB']LQDI'NLE'R'HAR'/SQSP

=> fil capl; d que lls  
FILE 'CAPLUS' ENTERED AT 12:21:54 ON 20 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Sep 2007 VOL 147 ISS 13  
FILE LAST UPDATED: 19 Sep 2007 (20070919/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>  
'OSI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE



CN L-Lysinamide, N-(1-oxooctyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-alanyl-L-histidyl-O-ethyl-L-tyrosyl-L-histidyl-L-ornithyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-histidyl-L-ornithyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoinomethyl)- (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTAHY HXVLXQLSAH XLLQDIXRX

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 1 L15 AND L19

L22 1 ANSWERS CAPLUS COPYRIGHT 2007 ACS ON STN  
TI Preparation of analogs of human growth hormone releasing hormone hGH-RH(1-29)NH2 having antagonistic activity for hGH-RH

this reference was printed in full with the inventor search

ALL ANSWERS HAVE BEEN SCANNED

# CLAIM 1

=> fil req: d que 19  
FILE 'REGISTRY' ENTERED AT 12:22:32 ON 20 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3  
DICTIONARY FILE UPDATES: 19 SEP 2007 HIGHEST RN 947584-60-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

L9 227 SEA FILE-REGISTRY ABB=ON [YH][R'CIT']DA[IV][FY'NAL']T[N'CIT']QS  
TA'ABU''AIB']...[K'ORN''HAR''CIT''NE'A]VL[GA'ABU''AIB''NLE'Q'C  
IT'H][OR]LS[A'ABU'] [HR'CIT'] [K'ORN''CIT'] [LA'AIB']LODI[ML'NLE'  
ABU''R][R'HAR'SNDA'ABU''CIT']./SOSP

=> fil capl: d que 116  
FILE 'CAPLUS' ENTERED AT 12:22:37 ON 20 SEP 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Sep 2007 VOL 147 ISS 13  
FILE LAST UPDATED: 19 Sep 2007 (20070919/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicv.html>  
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

L9 227 SEA FILE=REGISTRY ABB=ON [YH][R'CIT'DA[IV][FY'NAL']TIN'CIT'OS  
TA'ABU''AIB']...[K'ORN''HAR''CIT'NLE'A]VL[GA'ABU''AIB'NLE'Q'C  
IT'H][ORLS[A'ABU']][HR'CIT'] [K'ORN''CIT'] [LA'AIB']LODI[ML'NLE'  
ABU'R'] [R'HAR'SNDA'ABU''CIT'] /SQSP  
L14 73 SEA FILE=CAPLUS ABB=ON L9  
L16 49 SEA FILE=CAPLUS ABB=ON L14 AND (PY<2003 OR AY<2003 OR  
PRY<2003)

=> s l16 not l19,l15

L23 49 l16 NOT (L19 OR L15)

=> => d ibib abs hitseq l23 1-49; fil hom

L23 ANSWER 1 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:509747 CAPLUS Full-text

DOCUMENT NUMBER: 140:219

TITLE: Growth hormone-releasing hormone antagonists  
containing lactam bridge constraints

AUTHOR(S): Horvath, Judit E.; Toth, Katalin; Varga, Jozsef; Kele,  
Zoltan

CORPORATE SOURCE: Endocrine, Polypeptide and Cancer Institute,  
Department of Medicine, Tulane University, New  
Orleans, LA, USA

SOURCE: Peptides 2000, Proceedings of the European Peptide  
Symposium, 26th, Montpellier, France, Sept. 10-15,  
2000 (2001), Meeting Date 2000, 781-782.  
Editor(s): Martinez, Jean; Fehrentz, Jean-Alain.  
Editions EDK: Paris, Fr.

CODEN: 69EDWK; ISBN: 2-84254-048-4

DOCUMENT TYPE: Conference

LANGUAGE: English

AB The results of recent oncol. studies suggest a possible application of  
antagonists of human growth hormone-releasing hormone (hGH-RH) in the  
treatment of various human cancers. Previously, we reported the synthesis of  
various antagonists of GH-RH with high and protracted in vitro and in vivo  
activities. Based on the fact that i-(i+4) lactam bridge enhances the  
helicity of the central region of GH-RH, 10 new antagonistic analogs were  
synthesized in order to evaluate the influence of a lactam bridge constraint  
on the in vitro inhibiting potencies of hGH-RH antagonists.

IT 628316-44-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(growth hormone-releasing hormone antagonists containing lactam bridge  
constraints)

RN 628316-44-9 CAPLUS


CN L-Ornithinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-  
alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-(2S)-2-aminobutanoyl-  
L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutamyl-  
L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-  
D- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl-, (2S->29)-lactam  
(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)


SEQ 1 YRDAIFTXSY RKVLAQLSAR KLLQDIXSX

Absolute stereochemistry.


PAGE 1-A





PAGE 1-B



PAGE 1-C





REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 2 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:932781 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:198983  
 TITLE: Inhibitory effects of antagonistic analogs of GHRH on GH3 pituitary cells overexpressing the human GHRH receptor.  
 AUTHOR(S): Kovacs, M.; Schally, A. V.; Lee, E.-J.; Busto, R.; Armatis, P.; Groot, K.; Varga, J. L.  
 CORPORATE SOURCE: Endocrine, Polypeptide, Veterans Affairs Medical Center, New Orleans, LA, 70112, USA  
 SOURCE: Journal of Endocrinology (2002), 175(2), 425-434  
 CODEN: JOENAK; ISSN: 0022-0795  
 PUBLISHER: Society for Endocrinology  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB GH3 rat pituitary tumor cells produce GH and prolactin (PRL), but lack the GHRH receptor (GHRH-R). The authors expressed human GHRH-R (hGHRH-R) in GH3 cells using recombinant adenoviral vectors and studied the effects of GHRH antagonists. The mRNA expression of the GHRH-R gene in the cells was demonstrated by RT-PCR. An exposure of the GH3 cells infected with hGHRH-R to 10-10, 10-9 and 10-8 M hGHRH for 1 or 2 h in culture caused a dose-dependent elevation of the intracellular cAMP concentration and the cAMP efflux. Exposure to hGHRH also elicited dose-dependent increases in GH and PRL secretion from these cells. Neither the uninfected nor the antisense hGHRH-R-infected control cells exhibited cAMP, GH and PRL responses to GHRH

stimulation. GHRH antagonists JV-1-38 and JV-1-36 applied at 3 + 10-8 M for 3 h, together with 10-9 M GHRH, significantly inhibited the GHRH-stimulated cAMP efflux from the hGHRH-R-infected cells by 36 and 80% resp. The more potent antagonist JV-1-36 also decreased the intracellular cAMP levels in these cells by 55%. Exposure to JV-1-36 for 1 h nullified the stimulatory effect of GHRH on GH secretion and significantly inhibited it by 64 and 77% after 2 and 3 h resp. In a superfusion system, GHRH at 10-10, 10-9 and 10-8 M concns. induced prompt and dose-related high cAMP responses and smaller increases in the spontaneous GH secretion of the hGHRH-R-infected cells. Antagonists JV-1-36 and JV-1-38 applied at 3 + 10-8 M for 15 min, together with 10-9 M GHRH, inhibited the GHRH-stimulated cAMP response by 59 and 35% resp. This work demonstrates that GHRH antagonists can effectively inhibit the actions of GHRH on the hGHRH-R. The authors' results support the view that this class of compds. would be active clin.

IT 221377-79-3, JV-1-36 305322-14-9, JV-1-38  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 GH, prolactin and cAMP response to somatoliberin in GH3 pituitary cells overexpressing human GHRH receptor)  
 RN 221377-79-3 CAPLUS  
 CN L-Lysine, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L- $\alpha$ -aspartyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

RN 305322-14-9 CAPLUS  
 CN L-Lysine, N-(2-phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L- $\alpha$ -aspartyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRX

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2002:851683 CAPLUS Full-text  
 DOCUMENT NUMBER: 138:117932  
 TITLE: Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like

growth factor II  
Brackowski, Ryszard; Schally, Andrew V.; Plonowski, Artur; Varga, Jozsef L.; Groot, Kate; Krupa, Magdalena; Armatis, Patricia  
Endocrine, Polypeptide, and Cancer Institute, Veterans Affairs Medical Center, New Orleans, LA, USA  
Cancer (New York, NY, United States) (2002), 95(8), 1735-1745  
CODEN: CANCAR; ISSN: 0008-543X  
John Wiley & Sons, Inc.  
English  
Journal  
AB Antagonists of growth hormone-releasing hormone (GH-RH) can inhibit the proliferation of various tumors either indirectly through the suppression of the pituitary growth hormone/hepatic insulin-like growth factor I (IGF-I) axis and the lowering of serum IGF-I concentration or directly by reducing the levels of IGF-I and IGF-II and their mRNA expression in tumors and blocking the effect of autocrine GH-RH. In this study, the authors investigated the effects of the GH-RH antagonist JV-1-38 on MNNG/HOS human osteosarcoma and SK-ES-1 human Ewing sarcoma cell lines. Male nude mice bearing s.c. xenografts of MNNG/HOS or SK-ES-1 tumors were treated s.c. with JV-1-38 at a dose of 20 µg twice daily for 4 wk. The concns. of IGF-I and IGF-II in serum and in tumor tissue were measured by RIA. Tumor and liver levels of mRNA for IGF-I and IGF-II were determined by reverse transcriptase-polymerase chain reaction anal. The effects of JV-1-38, IGF-I, and IGF-II on cell proliferation in vitro were evaluated. GH-RH antagonist significantly inhibited the tumor volume and tumor weight of MNNG/HOS and SK-ES-1 tumors by >50% after 4 wk and increased tumor doubling time. JV-1-38 lowered the serum IGF-I level, decreased the expression of mRNA for IGF-I in the liver, and significantly reduced the concentration of IGF-II and mRNA levels for IGF-II in both sarcomas. The concentration of IGF-I was lowered only in SK-ES-1 tumors. In vitro, the proliferation of SK-ES-1 and MNNG/HOS cells was inhibited by JV-1-38 and by antisera to IGF-I and IGF-II. Thus, the inhibition of MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma by GH-RH antagonists was linked to a suppression of IGF-II production in tumors. However, in SK-ES-1 tumors, the effects on IGF-I also may be involved.  
IT 305322-14-9, JV-1-38  
RL: DNA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(growth hormone-releasing hormone antagonist inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines and involvement of IGF)  
RN 305322-14-9 CAPLUS  
CN L-lysine, N-(2-phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (CA INDEX NAME)  
NTE modified (modifications unspecified)  
SEQ 1 YRDAIFTHKY RKVLQLSAR KLLQIXRK

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
2002:711966 CAPLUS Full-text  
ACCESSION NUMBER: 137:367564  
DOCUMENT NUMBER:  
TITLE: The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas  
AUTHOR(S): Bustio, Rebeca; Schally, Andrew V.; Varga, Jozsef L.; Garcia-Fernandez, M. Olga; Groot, Kate; Armatis, Patricia; Szepeshazi, Karoly  
CORPORATE SOURCE: Endocrine, Polypeptide, Institute, Veterans Affairs Medical Center, and Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112, USA  
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2002), 99(18), 11866-11871  
CODEN: PNASAG; ISSN: 0027-8424  
National Academy of Sciences  
PUBLISHER: Journal  
DOCUMENT TYPE: English  
LANGUAGE: AB Splice variants (SVs) of receptors for growth hormone-releasing hormone (GHRH) have been found in primary human prostate cancers and diverse human cancer cell lines. GHRH antagonists inhibit growth of various expl. human cancers, including pancreatic and colorectal, xenografted into nude mice or cultured in vitro, and their antiproliferative action could be mediated in part through SVs of GHRH receptors. In this study we examined the expression of mRNA for GHRH and for SVs of its receptors in tumors of human pancreatic, colorectal, and gastric cancer cell lines grown in nude mice. mRNA for both GHRH and SV1 isoform of GHRH receptors was expressed in tumors of pancreatic (SW1990, PANC-1, MIA PaCa-2, Capan-1, Capan-2, and CFPAC1), colonic (COLO 320DM and HT-29), and gastric (NCI-N87, HS746T, and AGS) cancer cell lines; mRNA for SV2 was also present in Capan-1, Capan-2, CFPAC1, HT-29, and NCI-N87 tumors. In proliferation studies in vitro, the growth of pancreatic, colonic, and gastric cancer cells was stimulated by GHRH(1-29)NH2 and inhibited by GHRH antagonist JV-1-38. The stimulation of some gastroenteropancreatic cancer cells by GHRH was followed by an increase in cAMP production, and GHRH antagonist JV-1-38 competitively inhibited this effect. Our study indicates the presence of an autocrine/paracrine stimulatory loop based on GHRH and SV1 of GHRH receptors in human pancreatic, colorectal, and gastric cancers. The finding of SV1 receptor in human cancers provides an approach to an antitumor therapy based on the blockade of this receptor by specific GHRH antagonists.  
IT 305322-14-9, JV 1-38  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(GHRH antagonist; SV1 receptor in human cancers provides an approach to an antitumor therapy based on the blockade of this receptor by specific - GHRH antagonists)  
RN 305322-14-9 CAPLUS  
CN L-lysine, N-(2-phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (CA INDEX NAME)  
NTE modified (modifications unspecified)  
SEQ 1 YRDAIFTHKY RKVLQLSAR KLLQIXRK

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2002:641970 CAPLUS Full-text  
DOCUMENT NUMBER: 137:363625  
TITLE: Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: Lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor

AUTHOR(S): Plonowski, Artur; Schally, Andrew V.; Letsch, Markus; Krupa, Magdalena; Hebert, Francine; Busto, Rebecca; Groot, Kate; Varga, Jozsef L.

CORPORATE SOURCE: Veterans Affairs Medical Center, Endocrine, Polypeptide, and Cancer Institute, New Orleans, LA, USA

SOURCE: Prostate (New York, NY, United States) (2002

J. 52(3), 173-182

CODEN: PRSTD; ISSN: 0270-4137

Wiley-Liss, Inc.

PUBLISHER: Journal

DOCUMENT TYPE: English

LANGUAGE: English

AB Antagonists of growth hormone-releasing hormone (GHRH) such as JV-1-38 can inhibit androgen-independent prostate cancer directly by several mechanisms and/or indirectly by suppressing the GH/IGF-I axis. To shed more light on the mechanisms involved, the effects of JV-1-38 on PC-3 human prostate cancer were compared with those of somatostatin analog RC-160 in vivo and in vitro. Nude mice bearing PC-3 tumors received JV-1-38 (20 µg), RC-160 (50 µg) or a combination of JV-1-38 and RC-160. The concentration of IGF-I in serum and the expression of mRNA for IGF-II and VEGF in tumor tissue were investigated. In vivo, the final volume of PC-3 tumors treated with JV-1-38 was significantly lowered by 49%, whereas RC-160 exerted only 30% inhibition compared with controls. Combined use of both compounds augmented tumor inhibition to 63%. Serum IGF-I levels were decreased only in mice treated with RC-160. JV-1-38 suppressed mRNA for IGF-II in PC-3 tumors by 42%, whereas RC-160 alone or in combination with JV-1-38 caused a 65% reduction in IGF-II mRNA. JV-1-38 and RC-160 used as single drugs decreased the expression of VEGF by 50%, and their combination caused a 63% reduction. In vitro, JV-1-38 inhibited the proliferation of PC-3 cells by 39%. This effect could be partially reversed by addition of IGF-I to the serum-free medium. RC-160 alone did not affect the PC-3 cell growth in vitro, but in combination with JV-1-38 it augmented the antiproliferative effect of the GH-RH antagonist to 72%. Exposure to JV-1-38 in vitro reduced the expression of mRNA for IGF-II in PC-3 cells by 55% but did not change VEGF mRNA levels, whereas RC-160 had no effect.

IT 305322-14-9, JV-1-38

RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(GH-RH antagonist inhibition of proliferation of PC-3 human prostate cancer in relation to levels of serum IGF-I and expression of tumoral IGF-II and VEGF)

RN 305322-14-9 CAPLUS

CN L-Lysine, N-(2-phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAITPNKY RKVLXQLSAR KLLQDIXRK

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 6 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2002:52439 CAPLUS Full-text

DOCUMENT NUMBER: 136:210843

TITLE: Expression of a splice variant of the receptor for

GHRH in 3T3 fibroblasts activates cell proliferation

responses to GHRH analogs

Kiaris, Hippokratidis; Schally, Andrew V.; Busto,

Rebecca; Halmos, Gabor; Artavanis-Tsakonas, Spyros;

Varga, Jozsef L.

CORPORATE SOURCE: Harvard Medical School, Massachusetts General Hospital

Cancer Center, Charlestown, MA, 02129, USA

Proceedings of the National Academy of Sciences of the

United States of America (2002), 99(1),

196-200

CODEN: PNAS6; ISSN: 0027-8424

National Academy of Sciences

PUBLISHER: Journal

DOCUMENT TYPE: English

LANGUAGE: English

AB The stimulatory effects of growth hormone-releasing hormone (GHRH) and the antiproliferative action of GHRH antagonists have been demonstrated in various cancers, but the receptors that mediate these responses are not clearly identified. Recently, we reported that human cancer cell lines express splice variants (SVs) of the receptors for GHRH. SV1 exhibits the greatest similarity to the pituitary GHRH receptor and is most likely to be functional. To ascertain whether SV1 mediates mitogenic effects on nonpituitary tissues, we expressed SV1 in 3T3 mouse fibroblasts and studied the properties of the transfected cells. Radioligand binding assays with 125I-labeled GHRH antagonist JV-1-42 detected high affinity (Kd = 0.58 nM) binding sites for GHRH with a maximal binding capacity (Bmax) of 103 fmol/mg of membrane protein in 3T3 cells transfected with pCDNA3-SV1, whereas the control cells transfected with the empty vector did not show any GHRH binding. Cell proliferation studies showed that cells expressing SV1 are much more sensitive to GHRH analogs than the pCDNA3 controls. Thus, the expression of SV1 augments the stimulatory responses to GHRH (1-29)NH2 or GHRH agonist J1-38 and inhibitory responses to GHRH antagonist JV-1-38 as compared with pCDNA3 controls. The stimulation of SV1-expressing cells by GHRH or J1-38 is followed by an increase in cAMP production, but no GH release occurs. Vasoactive intestinal peptide had no effect, and its antagonist JV-1-53 did not inhibit the proliferation of SV1-expressing cells stimulated by GHRH. Our results suggest that SV1 could mediate responses of nonpituitary cells and various tumors to GHRH and GHRH antagonists. The presence of SV1 in several human cancer cell lines provides a rationale for antitumor therapy based on the blockade of this receptor by specific GHRH antagonists.

IT 221377-58-8, JV-1-42 305322-14-9, JV 1-38

RL: BSU (Biological study, unclassified); BIOL (Biological study)

(GHRH receptor splice variant expression in 3T3 fibroblasts activates

cell proliferation responses to GHRH analogs)

RN 221377-58-8 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-histidyl-D-arginyl-L-α-aspartyl-L-

alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-

10/566776

arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNRY RNVXQLSAR KLLQDIXRR

RN 305322-14-9 CAPLUS

CN L-lysine, N-(2-phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RNVXQLSAR KLLQDIXRR

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 7 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:846672 CAPLUS Full-text

DOCUMENT NUMBER: 136:144824

TITLE: Inhibition of growth and metastases of MDA-MB-435

human estrogen-independent breast cancers by an

antagonist of growth hormone-releasing hormone

Chatzistamou, Ioulia; Schally, Andrew V.; Varga,

Jozsef L.; Groot, Kate; Busto, Rebecca; Armatis,

Patricia; Halmos, Gabor

Endocrine, Polypeptide and Cancer Institute, Veterans

Affairs Medical Center, New Orleans, LA, 70112-1262,

USA

SOURCE: Anti-Cancer Drugs (2001), 12(9), 761-768

CODEN: ANTDEV; ISSN: 0959-4973

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Antagonists of growth hormone-releasing hormone (GH-RH) inhibit the growth of various cancers by mechanism(s) that include the suppression of the insulin-like growth factors (IGF)-I and/or -II. In this study, nude mice bearing orthotopic implants of MDA-MB-435 human estrogen-independent breast carcinoma received 39 days of therapy with GH-RH antagonist JV-1-36 (20 µg/day). The treatment significantly inhibited tumor growth by 71.1% (p<0.01) and nullified the metastatic potential of MDA-MB-435 cells. Four of eight control mice (50%) developed metastases in the lymph nodes and one (12.5%) in the lung, but none of the animals receiving JV-1-36 showed metastatic spread. GH-RH antagonist JV-1-36 inhibited the growth of MDA-MB-435 cells in vitro, while IGF-I stimulated it. However, mRNA for IGF-I or -II was not detected in MDA-MB-435 cells, indicating that the suppression of autocrine IGFs may not be involved in the antiproliferative mechanism. Using ligand competition assays with 125I-labeled GH-RH antagonist JV-1-42, specific high-affinity binding sites

47

10/566776

for GH-RH were found on tumor membranes. Reverse transcription-polymerase chain reaction revealed the expression of mRNA for GH-RH receptor splice variant-1 in MDA-MB-435 tumors. Our results suggest that the antitumorigenic action of GH-RH antagonists on MDA-MB-435 breast cancer could be direct and mediated by tumoral GH-RH receptors.

IT 221377-79-3, JV-1-36

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(inhibition of growth and metastases of MDA-MB-435 human

estrogen-independent breast cancers by GH-RH antagonist)

RN 221377-79-3 CAPLUS

CN L-lysine, N-(2-phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RNVXQLSAR KLLQDIXRR

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 8 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:797556 CAPLUS Full-text

DOCUMENT NUMBER: 137:87934

TITLE: Inhibition of growth and reduction in tumorigenicity

of UCI-107 ovarian cancer by antagonists of growth

hormone-releasing hormone and vasoactive intestinal

peptide

Chatzistamou, Ioulia; Schally, Andrew V.; Varga,

Jozsef L.; Groot, Kate; Armatis, Patricia; Bajó, Ana

VA Medical Center, Endocrine, Polypeptide and Cancer

Institute, New Orleans, LA, 70112-1262, USA

SOURCE: Journal of Cancer Research and Clinical Oncology (

2001), 127(11), 645-652

CODEN: JCR0D7; ISSN: 0171-5216

PUBLISHER: Springer-Verlag

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The tumor inhibitory activities of antagonists of growth hormone-releasing hormone (GH-RH) and vasoactive intestinal peptide (VIP) were evaluated in UCI-107 human ovarian cancer model, and the role of the insulin-like growth factor (IGF) system in the response was investigated. In the present study we investigated the effects of GH-RH antagonist JV-1-36 and VIP antagonist JV-1-52, on the growth and tumorigenicity of UCI-107 ovarian cell carcinoma xenografted into nude mice. Studies on the effects of hGH-RH(1-29)NH<sub>2</sub>, IGF-I, IGF-II, JV-1-36, and JV-1-52 on the proliferation of UCI-107 cells cultured in vitro were also performed. After 22 days of therapy with JV-1-36 or JV-1-52 at the dose of 20 µg/day, the final volume of UCI-107 tumors was significantly (p<0.05) decreased by 50.5% and 56%, resp., compared to controls. The concentration of IGF-II in tumors was reduced by 66% in the JV-1-36-treated group and by 62% in the group given JV-1-52 (both p<0.05). Exposure in vitro

48

to 1  $\mu$ M concns. of JV-1-36 or JV-1-52 for 24 h decreased the tumorigenicity of UCI-107 cells in nude mice. All ten mice injected with cells treated with medium alone developed tumors within 23 days after cell inoculation, while only eight of ten and four of ten mice injected with cells exposed to JV-1-36 or JV-1-52, resp., had tumors. In vitro exposure of UCI-107 cells to 5-35 ng/mL IGF-II produced a significant suppression in the rate of cell proliferation ( $P < 0.01$ ). Our results suggest that GH-RH and VIP antagonists inhibit the growth of UCI-107 ovarian cell carcinoma by mechanisms that appear to involve direct effects on the cancer cells.

IT 221377-79-3, JV-1-36

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(Inhibition of growth and reduction in tumorigenicity of UCI-107 ovarian cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide)

RN 221377-79-3 CAPLUS

CN L-Lysine, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 9 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:723866 CAPLUS Full-text

DOCUMENT NUMBER: 136:877

TITLE: Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth

AUTHOR(S): Szepeshazi, Karoly; Schally, Andrew V.; Armatas,

Patricia; Groot, Kate; Hebert, Francine; Feil, Anita;

Varga, Jozsef L.; Halmos, Gabor

Veterans Affairs Medical Center, Endocrine,

Polypeptide and Cancer Institute, New Orleans, LA,

70112, USA

SOURCE: Endocrinology (2001), 142(10), 4371-4378

CODEN: ENDOOJ ISSN: 0013-7227

DOCUMENT TYPE: Endocrine Society

LANGUAGE: English

AB The involvement of IGF-I in mammary carcinogenesis is well established, but the role of GH, as an autocrine growth factor for breast cancers is poorly understood. The goal of the authors' study was to investigate whether antagonists of GHRH can interfere with the effects of GH and IGF-I in MXT mouse mammary cancers. GHRH antagonists JV-1-36 and JV-1-38 inhibited growth of estrogen-independent MXT mouse mammary cancers in vivo, producing about 50% reduction in tumor volume. This growth inhibition was associated with a decrease in cell proliferation and an increase in apoptosis in MXT cancers. RIA and RT-PCR analyses showed that the concns. of GH and IGF-I and the levels

of mRNA for GH and IGF-I in MXT tumors were reduced by the therapy with GHRH antagonists. The mRNA for GH receptors was also decreased. In vitro, the proliferation of MXT cancer cells was strongly stimulated by GH and less effectively by IGF-I, indicating that both GH and IGF-I may act as growth factors for this mammary carcinoma. GHRH antagonist JV-1-38 inhibited the autonomous growth of MXT cells and the proliferation induced by IGF-I or GH and diminished 3H-thymidine incorporation stimulated by IGF-I and GH. These findings and a sustained increase in cyclin B2 concns. in the cells shown by immunoblotting indicate that JV-1-38 causes a block at the end of the G2 phase of cell cycle. The authors' results demonstrate that GHRH antagonists decrease the local production of both GH and IGF-I in MXT mouse mammary cancers, the resulting growth inhibition being the consequence of reduced cell proliferation and increased apoptosis.

IT 221377-79-3, JV-1-36 305322-14-9, JV 1-38

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(GHRH antagonists decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth)

RN 221377-79-3 CAPLUS

CN L-Lysine, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFNRY RKVLXQLSAR KLLQDIXRR

RN 305322-14-9 CAPLUS

CN L-Lysine, N-(2-phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT: 50 THERE ARE 50 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 10 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:407258 CAPLUS Full-text

DOCUMENT NUMBER: 135:266764

TITLE: Antiproliferative actions of growth hormone-releasing hormone antagonists on MiaPaCa-2 human pancreatic cancer cells involve cAMP independent pathways

AUTHOR(S): Rekasi, Z.; Varga, J. L.; Schally, A. V.; Plonowski,

A.; Halmos, G.; Csernus, B.; Armatas, P.; Groot, K.

Endocrine, Polypeptide and Cancer Institute, Veterans

Endocrine, Polypeptide and Cancer Institute, Veterans

SOURCE: Affairs Medical Center, New Orleans, LA, 70112, USA  
Peptides (New York, NY, United States) (2001  
). 22(6), 879-886

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB We evaluated the effects of GHRH antagonists on the proliferation of MiPaCa-2 human pancreatic cancer cells and cAMP signaling in vitro. GHRH antagonists inhibited the proliferation of MiPaCa-2 cells in vitro in a dose-dependent way and caused a significant elevation in cAMP production. In a superfusion system, short-term exposure of the cells to GHRH antagonists evoked an acute, dose-dependent release of cAMP into the medium. Native GHRH, which stimulates cAMP efflux from pituitary at nanomolar doses, did not influence cAMP release from cultured or superfused MiPaCa-2 cells even at 10-30 µM. VIP, PACAP, secretin and glucagon also did not influence cell proliferation or cAMP production. Adenylate cyclase activator forskolin (FSK) caused a greater cAMP response, but a smaller antiproliferative effect than GHRH antagonists. Combined treatment with FSK and GHRH antagonist JV-1-38 potentiated the cAMP-inducing effect of FSK, but did not produce a greater inhibition of cell proliferation than JV-1-38 alone. A selective accumulation of radiolabeled GHRH antagonist [125I]JV-1-42 in vivo in MiPaCa-2 carcinoma xenografted into nude mice was also observed. In conclusion, second messengers other than cAMP participate in the signal transduction pathways of GHRH analogs mediated by tumoral GHRH receptors.

IT 221377-57-7, MZ 6-55 221377-79-3, JV-1-36

305322-14-9, JV 1-38

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(antiproliferative actions of GHRH antagonists on MiPaCa-2 human pancreatic cancer cells involve cAMP independent pathways)

RN 221377-57-7 CAPLUS

CN L-lysine, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXRR

RN 221377-79-3 CAPLUS

CN L-lysine, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 305322-14-9 CAPLUS

CN L-lysine, N-(2-phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

IT 221377-58-8, JV-1-42

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(antiproliferative actions of GHRH antagonists on MiPaCa-2 human pancreatic cancer cells involve cAMP independent pathways)

RN 221377-58-8 CAPLUS

CN L-lysine, N-(phenylacetyl)-L-histidyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT: 40

THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 11 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2001:367559 CAPLUS Full-text

DOCUMENT NUMBER: 135:102703

TITLE: Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice

AUTHOR(S): Jozsef L.; Groot, Kate; Armatis, Patricia; Busto, Rebecca; Halmos, Gabor

CORPORATE SOURCE: Endocrine, Poly peptide, Veterans Affairs Medical Center, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112, USA

SOURCE: Journal of Clinical Endocrinology and Metabolism (2001), 86(5), 2144-2152

CODEN: JCEMAZ; ISSN: 0021-972X

PUBLISHER: Endocrine Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The effects of antagonists of GHRH and the somatostatin analog RC-160 on the growth of OV-1063 human epithelial ovarian cancer cells xenografted into nude

mice were investigated. Treatment with 20 µg/day of the GHRH antagonist JV-1-36 or MZ-5-156 and 60 µg/day of the somatostatin analog RC-160 for 25 days decreased tumor volume by 70.9% ( $P < 0.01$ ), 58.3% ( $P < 0.05$ ), and 60.6% ( $P < 0.01$ ), resp., vs. the control value. The levels of GH in serum were decreased in all of the treated groups, but only RC-160 significantly reduced serum insulin-like growth factor I (IGF-I). The levels of mRNA for IGF-I and -II and for their receptors in OV-1063 tumors were investigated by multiplex RT-PCR. No expression of mRNA for IGF-I was detected, but treatment with JV-1-36 caused a 51.8% decrease ( $P < 0.05$ ) in the level of mRNA for IGF-II in tumors. Exposure of OV-1063 cells cultured in vitro to GHRH, IGF-I, or IGF-II significantly ( $P < 0.05$ ) stimulated cell growth, but 10-5 M JV-1-36 nearly completely inhibited ( $P < 0.001$ ) OV-1063 cell proliferation. OV-1063 tumors expressed mRNA for GHRH receptors and showed the presence of binding sites for GHRH. Our results indicate that antagonistic analogs of GHRH and the somatostatin analog RC-160 inhibit the growth of epithelial ovarian cancers. The effects of RC-160 seem to be exerted more on the pituitary GH-hepatic IGF-I axis, whereas GHRH antagonists appear to reduce IGF-II production and interfere with the autocrine regulatory pathway. The antitumorigenic action of GHRH antagonists appears to be mediated by GHRH receptors found in OV-1063 tumors.

IT 221377-79-3, JV-1-36

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice)

RN 221377-79-3 CAPLUS

CN L-Lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAITNRY RKVLXLSAR KLLQIXRR

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 12 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:829867 CAPLUS Full-text

DOCUMENT NUMBER: 134:216921

TITLE: Suppression of tumor growth by growth hormone-releasing hormone antagonist JV-1-36 does not involve the inhibition of autocrine production of insulin-like growth factor II in H-69 small cell lung carcinoma

AUTHOR(S): Kiaris, H.; Schally, A. V.; Varga, J. L.

CORPORATE SOURCE: Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, New Orleans, LA, 70112-1262, USA

SOURCE: Cancer Letters (Shannon, Ireland) (2000),

161(2), 149-155

CODEN: CALEDQ: ISSN: 0304-3835

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Although a high antitumor activity of growth hormone releasing hormone (GHRH) antagonists has been demonstrated in various tumors, the mechanism of action of these peptide analogs remains poorly understood. An association has been observed between the antitumor effects of GHRH antagonists and the inhibition of insulin-like growth factors (IGFs), but it is not clear whether the suppression of IGFs is obligatory for the action of GHRH antagonists. In the present study we investigated various components of the IGF system in H-69 small cell lung carcinoma (SCLC) xenografted into nude mice and treated with GHRH antagonist JV-1-36. After 31 days of treatment with JV-1-36, tumor weight was inhibited by about 70% as compared with the controls. Reverse transcription-polymerase chain reaction (RT-PCR) anal. indicated that H-69 tumors express mRNAs for IGF-II and IGF-receptors- (IGFR-) I and II, but not for IGF-I. The levels of mRNA for IGF-II and IGF-I and -II were not affected by the treatment with JV-1-36. Exposure to antibody IIR, which blocks the binding of IGF-I and -II to IGFR-I, inhibited the proliferation of H-69 cells in vitro, indicating that IGF-II present in the tumors might stimulate the proliferation of H-69 SCLC in an autocrine manner. Collectively our results suggest that inhibition of tumor growth by GHRH antagonists is not associated with the suppression of the autocrine stimulation by IGF-II in H-69 SCLC.

IT 221377-79-3, JV-1-36

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(mechanism of tumor growth suppression by growth hormone-releasing hormone antagonist JV-1-36)

RN 221377-79-3 CAPLUS

CN L-Lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAITNRY RKVLXLSAR KLLQIXRR

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 13 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:824291 CAPLUS Full-text

DOCUMENT NUMBER: 134:21425

TITLE: Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components

INVENTOR(S): Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter

PATENT ASSIGNEE(S): G.; Holmes, Darren L.; Thibadeau, Karen

SOURCE: Conjuchem, Inc., Can.

PCT Int. Appl., 733 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069900	A2	20001123	WO 2000-0513576	20000517 <--
WO 2000069900	A3	20010215		
WO 2000069900	A9	20020704		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, GE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373252	A1	20001123	CA 2000-2373252	20000517 <--
CA 2373252	C	20070807		
CA 2373680	A1	20001123	CA 2000-2373680	20000517 <--
CA 2499211	A1	20001123	CA 2000-2499211	20000517 <--
CA 2501421	A1	20001123	CA 2000-2501421	20000517 <--
CA 2505617	A1	20001123	CA 2000-2505617	20000517 <--
WO 2000070665	A2	20001123	WO 2000-18763	20000517 <--
WO 2000070665	A3	20010419		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, GE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1105409	A2	20010613	EP 2000-936023	20000517 <--
EP 1105409	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
EP 1171582	A2	20020116	EP 2000-929748	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1264840	A1	20021211	EP 2002-14617	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003500341	T	20030107	JP 2000-619018	20000517 <--
JP 2003500350	T	20030304	JP 2000-618316	20000517 <--
AU 765753	B2	20030925	AU 2000-51393	20000517 <--
EP 1591433	A1	20051102	EP 2005-105384	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
CN 1698881	A	20051123	CN 2005-10005990	20000517 <--
EP 1598365	A1	20051123	EP 2005-105387	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1623994	A2	20060208	EP 2005-108328	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
AT 318835	T	20060315	AT 2000-936023	20000517 <--
PT 1105409	T	20060731	PT 2000-936023	20000517 <--
ES 2257298	T3	20060801	ES 2000-936023	20000517 <--
US 6849714	B1	20050201	US 2000-623548	20000905 <--
US 6514500	B1	20030204	US 2000-657332	20000907 <--
US 7090851	B1	20060815	US 2000-657336	20000907 <--

US 7144854	B1	20061205	US 2000-657431	20000907 <--
ZA 2001006676	A	20020719	ZA 2001-6676	20010814 <--
ZA 2001009110	A	20020613	ZA 2001-9110	20011105 <--
US 2003108567	A1	20030612	US 2002-287892	20021104 <--
US 6821949	B2	20041123		
US 2003108568	A1	20030612	US 2002-288340	20021104 <--
US 6887849	B2	20050503		
US 2004127398	A1	20040701	US 2003-722733	20031125 <--
US 2004138100	A1	20040715	US 2003-723099	20031125 <--
US 2005176641	A1	20050811	US 2005-40810	20050121 <--
JP 2005263807	A1	20050811	US 2005-67556	20050225 <--
JP 2005263807	A	20050929	JP 2005-115175	20050412 <--
JP 2005263807	A	20050929	JP 2005-140407	20050512 <--
JP 2005263807	A	20050929	JP 2005-151458	20050524 <--
JP 2005263807	A	20050929	JP 2005-170967	20050629 <--
US 2006009377	A1	20060112	US 2005-215967	20050830 <--
US 2006058235	A1	20060316	US 2005-361126	20051214 <--
JP 2006151986	A	20060615	US 2005-304446	20051214 <--
US 2006135428	A1	20060622	US 2006-350703	20060208 <--
US 2006135428	A1	20060622	US 1999-134406P	P 19990517 <--
PRIORITY APPEN. INFO.:				
US 1999-134406P			US 1999-153406P	P 19990910 <--
US 1999-153406P			US 1999-159783P	P 19991015 <--
CA 2000-2363712	A3	20000517 <--	CA 2000-2373680	A3 20000517 <--
CA 2000-2373680	A3	20000517 <--	CN 2000-807671	A3 20000517 <--
EP 2000-932570	A3	20000517 <--	EP 2000-932570	A3 20000517 <--
EP 2000-936023	A3	20000517 <--	EP 2000-936023	A3 20000517 <--
JP 2000-618316	A3	20000517 <--	JP 2000-618316	A3 20000517 <--
JP 2000-618327	A3	20000517 <--	JP 2000-618327	A3 20000517 <--
WO 2000-18763	W	20000517 <--	WO 2000-18763	W 20000517 <--
WO 2000-18763	W	20000517 <--	WO 2000-18763	W 20000517 <--
US 2000-623543	A1	20000905 <--	US 2000-623543	A1 20000905 <--
US 2000-623548	A1	20000905 <--	US 2000-623548	A1 20000905 <--
US 2000-657276	A2	20000907 <--	US 2000-657276	A2 20000907 <--
US 2000-657332	A3	20000907 <--	US 2000-657332	A3 20000907 <--
US 2000-657431	A1	20000907 <--	US 2000-657431	A1 20000907 <--
US 2002-400199P	P	20020731 <--	US 2002-400199P	P 20020731 <--
US 2002-400413P	P	20020731 <--	US 2002-400413P	P 20020731 <--
US 2002-288340	A1	20021104 <--	US 2002-288340	A1 20021104 <--
WO 2003-CAL097	W	20030729	WO 2003-CAL097	W 20030729
US 2003-471348	B1	20030908	US 2003-471348	B1 20030908
US 2003-722733	A1	20031125	US 2003-722733	A1 20031125
US 2005-40810	A2	20050121	US 2005-40810	A2 20050121
US 2005-170967	A1	20050629	US 2005-170967	A1 20050629
US 2005-215967	A1	20050830	US 2005-215967	A1 20050830

AB A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide is modified by attaching a reactive group to the C-terminus amino acid, to the N-terminus amino acid, or to an amino acid located between the N-terminus and the C-terminus, such that the modified peptide is capable of forming a covalent bond in vivo with a reactive functionality on a blood component. The solid phase peptide synthesis of a number of derivs. with 3-maleimidopropionic acid (3-MPA) is described. In the next step, a covalent bond is formed between the reactive group and a reactive functionality on a blood component to form a peptide-blood component conjugate, thereby protecting said peptide from peptidase activity. The final step of the method involves the analyzing of the stability of the peptide-blood component conjugate to assess the protection of the peptide from peptidase activity. Thus, the percentage of a

K5 kringle peptide (Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>) conjugated to human serum albumin via MPA remained relatively constant through a 24-h plasma assay in contrast to unmodified K5 which decreased to 9% of the original amount of K5 in only 4 h in plasma.

IT

309244-12-0

RL: PRP (Properties)

(unclained sequence; protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components)


RN 309244-12-0 CAPLUS

CN 114: PN: W00069900 SEQID: 118 unclained sequence (9CI) (CA INDEX NAME)


SEQ 1 YRDAIFTNSY RKVLGQLSAR KLLQDIMSR

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A




PAGE 3-A



PAGE 3-B



PAGE 4-A



L23 ANSWER 14 OF 49 CAPLUS: COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:664852 CAPLUS Full-text

DOCUMENT NUMBER: 133:348337

TITLE: Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone

AUTHOR(S): Halmos, Gabor; Schally, Andrew V.; Varga, Jozsef L.;

Plonowski, Artur; Rekasi, Zoltan; Czompoli, Tamas

CORPORATE SOURCE: Endocrine, Polypeptide and Cancer Institute, Veterans

Affairs Medical Center, Tulane University School of

Medicine, New Orleans, LA, 70112-2699, USA

SOURCE: Proceedings of the National Academy of Sciences of the

United States of America (2000), 97(19),

10555-10560

CODEN: PNAS6; ISSN: 0027-8424

National Academy of Sciences

Journal

English

PUBLISHER:

DOCUMENT TYPE:

LANGUAGE:

AB Antagonists of growth hormone-releasing hormone (GHRH) inhibit the proliferation of various human cancers in vitro and in vivo by mechanisms that include apparent direct effects through specific binding sites expressed on tumors and that differ from pituitary human GHRH (hGHRH) receptors. In this study, GHRH antagonist JV-1-38 (20 µg/day per animal s.c.) inhibited the growth of orthotopic Caki-1 human renal cell carcinoma (RCC) by 83% and inhibited the development of metastases to lung and lymph nodes. Using ligand competition assays with 125I-labeled GHRH antagonist JV-1-42, the authors demonstrated the presence of specific high-affinity ( $K_d = 0.25$  nM) binding sites for GHRH with a maximal binding capacity ( $B_{max}$ ) of 70.2 fmol/mg of membrane protein in Caki-1 tumors. These receptors bind GHRH antagonists preferentially and display a lower affinity for hGHRH. The binding of 125I-JV-1-42 is not inhibited by vasoactive intestinal peptide (VIP)-related peptides sharing structural homol. with hGHRH. The receptors for GHRH antagonists on Caki-1 tumors are distinct from binding sites detected with 125I-VIP ( $K_d = 0.89$  nM;  $B_{max} = 183.5$  fmol/mg of protein) and also have different characteristics from GHRH receptors on rat pituitary as documented by the insignificant binding of [His<sup>1</sup>,125I-Tyr<sup>10</sup>,Nle<sup>27</sup>]hGHRH(1-32)NH<sub>2</sub>. Reverse transcription-PCR revealed the expression of splice variants of hGHRH receptor in Caki-1 RCC. Biodistribution studies demonstrate an in vivo uptake of 125I-JV-1-42 by the RCC tumor tissue. The presence of specific receptor proteins that bind GHRH antagonists in Caki-1 RCC supports the view that distinct binding sites that mediate the inhibitory effect of GHRH antagonists are present on various human cancers.

IT 221377-38-6, JV 1-42 221377-79-3, JV 1-36

305322-14-9, JV 1-38

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone and antagonists distinct from growth hormone-releasing hormone receptor)

RN 221377-38-8 CAPLUS

CN L-lysineamide, N-(phenylacetyl)-L-histidyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arganyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-79-3 CAPLUS

CN L-lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl) -L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-leucyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 305322-14-9 CAPLUS

CN L-lysine, N-(2-phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl) -L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-leucyl-L-leucyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl) - (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT:

40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 15 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:545266 CAPLUS Full-text

DOCUMENT NUMBER: 134:240

TITLE:

Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice

AUTHOR(S):

Klarris, Hippokratris; Schally, Andrew V.; Varga, Jozsef L.

CORPORATE SOURCE:

Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center and Section of Experimental Medicine, Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA  
Neoplasia (New York) (2000), 2(3), 242-250  
CODEN: NEOPFL; ISSN: 1522-8002

SOURCE:

PUBLISHER:

Nature America Inc.

DOCUMENT TYPE:

LANGUAGE:

English

AB Antagonists of growth hormone-releasing hormone (GH-RH) inhibit the growth of various cancers by mechanisms that involve the suppression of the insulin-like growth factor (IGF)-I and/or IGF-II. In view of the importance of the IGF system in glioma tumorigenesis, the effects of GH-RH antagonists MZ-5-156 and JV-1-36 were investigated in nude mice bearing s.c. and ortho-topic xenografts of U-87MG human glioblastomas. After 4 wk of therapy with MZ-5-156 or JV-1-36 at the dose of 20 µg/day per animal, the final volume of s.c. U-87MG tumors was significantly ( $P < .01$ ) decreased by 84% and 76%, resp., as compared with controls. Treatment with GH-RH antagonists also reduced tumor weight and the levels of mRNA for IGF receptor type I (IGF-R-I). A reduction in the mRNA levels for IGF-II was found in tumors of mice treated with MZ-5-156.

Treatment with MZ-5-156 or JV-1-36 also extended the survival of nude mice implanted ortho-topically with U-87MG glioblastomas by 81% ( $P < .005$ ) and 18%, resp., as compared with the controls. Exposure in vitro to GH-RH antagonists MZ-5-156 or JV-1-36 at 1 µM concentration for 24 h decreased the tumorigenicity of U-87MG cells in nude mice by 10% to 30% and extended the latency period for the development of s.c. palpable tumors by 31% to 56%, as compared with the controls. Exposure of U-87MG cells to GH-RH antagonists in vitro also resulted in a time-dependent increase in the mRNA levels of IGF-R-II

or a decrease in the mRNA levels of IGFR-I. mRNA for GH-RH was detected in U-87MG cells and xenografts implying that GH-RH may play a role in the pathogenesis of this tumor. Our results suggest that GH-RH antagonists M2-5-156 and JV-1-36 inhibit the growth of U-87MG human glioblastoma by mechanisms that involve the suppression of IGF system. Antagonistic analogs of GH-RH merit further development for the treatment of malignant glioblastoma.

IT 221377-79-3, JV 1-36  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(antagonists of GHRH inhibit growth of human glioblastoma in nude mice)

RN 221377-79-3 CAPLUS  
CN L-lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 16 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2000:521514 CAPLUS Full-text

DOCUMENT NUMBER: 133:217935

TITLE: Antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide inhibit tumor proliferation by different mechanisms: evidence from in vitro studies on human prostatic and pancreatic cancers

AUTHOR(S): Rekas, Zoltan; Varga, Jozsef L.; Schally, Andrew V.; Halmos, Gabor; Armatis, Patricia; Groot, Kate; Crompoli, Tamas

CORPORATE SOURCE: Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, and Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112, USA

SOURCE: Endocrinology (2000), 141(6), 2120-2128

CODEN: ENDOAO; ISSN: 0013-7227

PUBLISHER: Endocrine Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Antagonists of GH-releasing hormone (GHRH) and vasoactive intestinal peptide (VIP) inhibit the proliferation of various tumors in vitro and in vivo, but a comparison of their antitumor effects and mechanisms of action has not been reported to date. The authors recently synthesized and characterized a series of analogs, some of which are primarily GHRH antagonists (JV-1-36, JV-1-38, and JV-1-42), whereas others are more selective for VIP receptors (VPAC-R; JV-1-50, JV-1-51, and JV-1-52, and JV-1-53). LNCap human prostatic cancer cells express VPAC-R, with predominant subtype 1 determined by RT-PCR. The authors' studies show that GHRH antagonists significantly inhibit the proliferation of both VPAC-R pos. LNCap cells ( $P < 0.001$ ) and VPAC-R neg. MdaPca-2 human pancreatic cancer cells cultured in vitro ( $P < 0.05$  to  $P < 0.001$ ). Growth inhibition of LNCap cells is accompanied by a proportional reduction in prostate-specific antigen (PSA) secretion ( $P < 0.001$ ). In a superfusion

system, the inhibitory activities of the analogs on the rate of VIP and GHRH-induced PSA secretion correlate well with their VPAC-R binding affinities to LNCap cell membranes. Antagonists more selective for VPAC-R display a stronger inhibition of inducible PSA release than GHRH antagonists, but have smaller effects or no effects on proliferation and PSA secretion in culture. Collectively, the authors' findings demonstrate that the antiproliferative activity of the analogs on cancer cells is not correlated to their VPAC-R antagonistic potencies. Because GHRH antagonists inhibit the proliferation of LNCap cells more powerfully than VPAC-R antagonists and also suppress the growth of VPAC-R neg. MdaPca-2 cells, it can be concluded that their antiproliferative effect is exerted through a mechanism independent of VPAC-R.

IT 221377-58-8 221377-59-9 221377-79-3

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)

(GH-RH antagonists inhibit tumor proliferation more powerfully than VIP receptor antagonists suggesting VIP receptor independent mechanism in human prostatic and pancreatic cancer cell lines)

RN 221377-58-8 CAPLUS

CN L-lysineamide, N-(phenylacetyl)-L-histidyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-59-9 CAPLUS

CN L-lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-79-3 CAPLUS

CN L-lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparagyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 17 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:430815 CAPLUS Full-text  
 DOCUMENT NUMBER: 133:290719  
 TITLE: Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice  
 AUTHOR (S): Kahan, Zsuzsanna; Varga, Jozsef L.; Schally, Andrew V.; Rekasi, Zoltan; Armatis, Patricia; Chatzistamou, Ioulia; Crompoly, Tamas; Halmos, Gabor  
 CORPORATE SOURCE: Veterans Affairs Medical Center, Endocrine, Polypeptide and Cancer Institute, New Orleans, LA, USA  
 SOURCE: Breast Cancer Research and Treatment (2000), 60(1), 71-79  
 CODEN: BCTRD6; ISSN: 0167-6806  
 PUBLISHER: Kluwer Academic Publishers  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Since antagonists of growth hormone-releasing hormone (GH-RH) inhibit proliferation of various tumors, in this study we investigated the effects of GH-RH antagonists MZ-5-156 or JV-1-36 on growth of estrogen-independent MDA-MB-468 human breast cancers xenografted into nude mice. Both GH-RH antagonists administered at a dose of 20 µg/day induced regression of some and growth arrest of other tumors, while control tumors continued to grow. After 5 wk of therapy with MZ-5-156 or JV-1-36, final volume and weight of MDA-MB-468 tumors were significantly decreased (all p values < 0.001) and serum IGF-I levels as well as tumor IGF-I mRNA expression were reduced as compared with controls. High affinity binding sites for IGF-I were detected by the ligand binding method. Gene expression of human IGF-I receptors, as measured by the RT-PCR, was not significantly different in control and treated MDA-MB-468 tumors. In cell culture, IGF-I did not stimulate, GH-RH slightly stimulated, while MZ-5-156 and JV-1-36 inhibited proliferation of MDA-MB-468 cells known to possess defective insulin and IGF-I receptor signaling. The expression of mRNA for human GH-RH was found in five of 8 tumors treated with GH-RH antagonists, and in one of the five control tumors. These results suggest that GH-RH antagonists inhibit MDA-MB-468 breast cancers possibly through mechanisms involving interference with locally produced GH-RH.  
 IT 221377-79-3, JV 1-36  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (221377793; GH-RH antagonists inhibition of estrogen-independent human breast cancer)  
 RN 221377-79-3 CAPLUS  
 CN L-Lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 18 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 2000:384335 CAPLUS Full-text  
 DOCUMENT NUMBER: 133:130085  
 TITLE: Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers  
 AUTHOR (S): Szepeshazi, K.; Schally, A. V.; Groot, K.; Armatis, P.; Halmos, G.; Hebert, F.; Szende, B.; Varga, J. L.; Zarandi, M.  
 CORPORATE SOURCE: Veterans Affairs Medical Center, Endocrine, Polypeptide and Cancer Institute, New Orleans, LA, 70112-1262, USA  
 SOURCE: British Journal of Cancer (2000), 82(10), 1724-1731  
 CODEN: BJCAAI; ISSN: 0007-0920  
 PUBLISHER: Harcourt Publishers Ltd.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Insulin-like growth factors (IGFs) I and II are implicated in progression of various tumors including colorectal carcinomas. To interfere with the production of IGFs, the authors treated nude mice bearing xenografts of HT-29 human colon cancer with various potent growth hormone-releasing hormone (GH-RH) antagonists. Twice daily injections of antagonist MZ-4-71, 10 µg i.p. or 5 µg s.c. resulted in a significant 43-45% inhibition of tumor growth. Longer acting GH-RH antagonists, MZ-5-156 and JV-1-36 given once daily at doses of 20 µg s.c. produced a 43-58% decrease in volume and weight of cancers. Histol. analyses of HT-29 cancers demonstrated that both a decreased cell proliferation and an increased apoptosis contributed to tumor inhibition. GH-RH antagonists did not change serum IGF-I or IGF-II levels, but significantly decreased IGF-II concentration and reduced mRNA expression for IGF-II in tumors. In vitro studies showed that HT-29 cells produced and secreted IGF-II into the medium, and addition of MZ-5-156 dose-dependently decreased IGF-II production by about 40% as well as proliferation of HT-29 cells. The authors' studies demonstrate that GH-RH antagonists inhibit growth of HT-29 human colon cancers in vivo and in vitro. The effect of GH-RH antagonists may be mediated through a reduced production and secretion of IGF-II by cancer cells.  
 IT 190791-06-1 286850-19-9  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (antagonists of growth hormone-releasing hormone inhibit IGF-II production and growth of HT-29 human colon cancers)  
 RN 190791-06-1 CAPLUS  
 CN 1-29-Somatoliberin (human pancreatic islet), N-(phenylacetyl)-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-L-alanine-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)  
 NTE modified  
 SEQ 1 YRDAIFTNSY RKVLAQLSAR KLLQDIXSR



RN 286850-19-9 CAPLUS  
CN L-Arginamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl- (9CI)  
(CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAITNRY RKVLXLSAR KLLQDIXSR

REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 19 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2000:284018 CAPLUS Full-text  
DOCUMENT NUMBER: 132:303894  
TITLE: Antagonistic analogs of GH-RH inhibiting IGF-I and -II  
INVENTOR(S): Schally, Andrew V.; Varga, Jozsef; Zarándi, Márta  
PATENT ASSIGNEE(S): The Administrators of the Tulane Educational Fund, USA  
SOURCE: U.S., 17 pp.  
CODEN: USXXAM

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6057422	A	20000502	US 1998-199381	19981125 <--
CA 2351665	A1	20000602	CA 1998-2351665	19991123 <--
WO 2000031136	A1	20000602	WO 1999-US27822	19991123 <--
W: AU, BG, BR, BY, CA, CN, CZ, EE, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LV, MK, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, UZ, YU, ZA, AM, AG, MD, TJ, TM				
RM: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
BR 9915512	A	20010807	BR 1998-15512	19991123 <--
EP 1133522	A1	20010919	EP 1998-963962	19991123 <--
EP 1133522	B1	20060705		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
TR 200101492	T2	20011121	TR 2001-200101492	19991123 <--
HU 200105094	A2	20020429	HU 2001-5094	19991123 <--
JP 2002530432	T	20020917	JP 2000-583962	19991123 <--
AU 757222	B2	20030206	AU 2000-20291	19991123 <--
AU 2235099	C2	20040827	AU 2001-117218	19991123 <--
NZ 511307	A	20050128	NZ 1999-511307	19991123 <--
AT 332310	T	20060715	AT 1998-963962	19991123 <--
ES 2264279	T3	20061216	ES 1998-963962	19991123 <--
TW 585873	B	20040501	TW 1998-88120503	19991124 <--
US 7026281	B1	20060411	US 2000-547215	20000411 <--
NO 2001002489	A	20010704	NO 2001-2489	20010521 <--
MX 2001PA05212	A	20000821	MX 2001-PA5212	20010524 <--
BG 105638	A	20020131	BG 2001-105638	20010622 <--

BG 65137 B1 20070330  
HK 1036461 A1 20060915  
IN 2001KN00563 A 20060616  
PRIORITY APPLN. INFO.: US 1998-199381 A 19981125 <--  
WO 1999-US27822 W 19991123 <--

OTHER SOURCE(S): MARPAT 132:303894

AB There is provided a novel series of synthetic analogs of hGH-RH(1-29) NH2. These analogs inhibit the activity of endogenous hGH-RH, and therefore prevent the release of growth hormone. The stronger inhibitory potencies of the new analogs, as compared to previously described ones, results from replacement of various amino acids. The GH-RH antagonists are effective in treating cancer, for example human cancers of the breast, lung, colon, brain, pancreas, and prostate where the receptors for IGF-I or IGF-II are present.

IT 221377-28-2P 221377-49-7P 221377-52-2P  
221377-57-7P 221377-58-8P 221377-59-9P  
221377-60-2P 221377-76-0P 221377-77-1P  
221377-78-2P 221377-79-3P 221377-80-6P  
265307-63-9P 265307-91-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of antagonistic analogs of GH-RH inhibiting IGF-I and -II for use in treating cancer)

RN 221377-28-2 CAPLUS

CN D-Arginamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-arginyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAITNRY RKVLXLSAR KLLQDIXSR

RN 221377-49-7 CAPLUS

CN D-Arginamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-norleucyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAITNRY RKVLXLSAR KLLQDIXSR

RN 221377-52-2 CAPLUS

CN D-Arginamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-57-7 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXRR

RN 221377-58-8 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-histidyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-59-9 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-60-2 CAPLUS

CN L-Lysinamide, N-(1-naphthalenylacetyl)-L-histidyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-76-0 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-77-1 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-78-2 CAPLUS

CN L-Lysinamide, N-(1H-indol-3-ylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-79-3 CAPLUS

CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9Ci) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-80-6 CAPLUS  
CN L-Lysineamide, N-(1-naphthalenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 265307-63-9 CAPLUS  
CN D-Arginineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 265307-91-3 CAPLUS  
CN D-Arginineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-D-arginyl-L-arginyl- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 20 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 2000:99362 CAPLUS Full-text  
DOCUMENT NUMBER: 132:217257  
TITLE: Antagonistic actions of analogs related to growth hormone-releasing hormone (GHRH) on receptors for GHRH and vasoactive intestinal peptide on rat pituitary and pineal cells in vitro  
AUTHOR(S): Rekasi, Zoltan; Varga, Jozsef L.; Schally, Andrew V.; Halmos, Gabor; Groot, Kate; Czompoly, Tamas  
CORPORATE SOURCE: Endocrine, Polypeptide and Cancer Institute, Veterans Affairs Medical Center, and Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70112, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2000), 97(3), 1218-1223  
CODEN: PNAS6; ISSN: 0027-8424  
PUBLISHER: National Academy of Sciences  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Peptide analogs of growth hormone-releasing hormone (GHRH) can potentially interact with vasoactive intestinal peptide (VIP) receptors (VPAC1-R and VPAC2-R) because of the structural similarities of these two hormones and their receptors. The authors synthesized four new analogs related to GHRH (JV-1-50, JV-1-51, JV-1-52, and JV-1-53) with decreased GHRH antagonistic activity and increased VIP antagonistic potency. To characterize various peptide analogs for their antagonistic activity on receptors for GHRH and VIP, the authors developed assay systems based on superfusion of rat pituitary and pineal cells. Receptor-binding affinities of peptides to the membranes of these cells were also evaluated by radioligand competition assays. Previously reported GHRH antagonists JV-1-36, JV-1-38, and JV-1-42 proved to be selective for GHRH receptors, because they did not influence VIP-stimulated VPAC2 receptor-dependent prolactin release from pituitary cells or VPAC1 receptor-dependent cAMP efflux from pinealocytes but strongly inhibited GHRH-stimulated growth hormone (GH) release. Analogs JV-1-50, JV-1-51, and JV-1-52 showed various degrees of VPAC1-R and VPAC2 antagonistic potency, although also preserving a substantial GHRH antagonistic effect. Analog JV-1-53 proved to be a highly potent VPAC1 and VPAC2 receptor antagonist, devoid of inhibitory effects on GHRH-evoked GH release. The antagonistic activity of these peptide analogs on processes mediated by receptors for GHRH and VIP was consistent with the binding affinity. The analogs with antagonistic effects on different types of receptors expressed on tumor cells could be utilized for the development of new approaches to treatment of various human cancers.

IT 221377-58-8 221377-59-9 221377-79-3  
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BPL (Biological study); PROC (Process); USES (Uses) (antagonistic actions of GHRH analogs on receptors for GHRH and VIP in rat pituitary and pineal cells in vitro)

RN 221377-58-8 CAPLUS  
CN L-Lysineamide, N-(phenylacetyl)-L-histidyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-59-9 CAPLUS  
CN L-Lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-79-3 CAPLUS  
CN L-Lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-N6-(aminoiminomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 21 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1999:396688 CAPLUS Full-text  
DOCUMENT NUMBER: 131:209293  
TITLE: Systematic lactam scan of hGRF 1-29-NH2 yields potent agonists and antagonists

AUTHOR(S): Cervini, L.; Donaldson, C.; Koerber, S.; Vale, W.; Rivier, J.

CORPORATE SOURCE: Clayton Foundation Laboratories for Peptide Biology, The Salk Institute, La Jolla, CA, 92037, USA  
SOURCE: Peptides: Frontiers of Peptide Science, Proceedings of the American Peptide Symposium, 15th, Nashville, June 14-19, 1997 (1997), Meeting Date 1997, 637-638. Editor(s): Tam, James P.; Kaumaya, Pravin T. P. Kluwer: Dordrecht, Neth.  
CODEN: 67UCAR

DOCUMENT TYPE: Conference  
LANGUAGE: English  
AB The authors present a complete i-(1 + 3) lactam scan of [MeTyr1, Ala15, Glu1, Lys1+3, Nle27]hGRF(1-29)-NH2. Potencies for the 26 analogs in this series were compared to that of the agonist standard hGRF(1-40)-OH. The most potent analogs were those with i-(1 + 3) cycles between residues 4-7, 5-8, 9-12, 16-19, 21-24, 22-25 and 25-28. Three antagonists were designed by including point substitutions (Darg2 and Cpa6) in representative, potent cyclic analogs of the lactam scan. The compds. are [MeTyr1, Darg2, Cpa6, Nle27]-rGRF1-29NH2 standard (1), c(22- 25)[MeTyr1, Darg2, Cpa6, Ala15, Glu22, Lys25, Nle27] (2), c(25- 28)[MeTyr1, Darg2, Cpa6, Ala15, 22, Glu25, Nle27, Lys28] (3), and c(25- 29)[MeTyr1, Darg2, Cpa6, Ala15, 22, DAsp25, Nle27, Orn29] (4). The i-(1 + 4) analog 4 is half as potent as analogs 2 and 3 with smaller cycles, and all three bridging scaffolds yielded relatively more potent agonists than antagonists. In conclusion, modifications that produce increased agonist potencies may also produce potent antagonists, albeit to a slightly lesser degree. These antagonists exemplify the application of SAR scan data to rationally design potent analogs and provide a useful tool for probing the structural requirements necessary for GRF receptor binding. Conformational restriction yields subtle effects in the peptide-receptor interaction, but bridging elements in a peptide.  
IT 243132-98-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study) (systematic lactam scan of hGRF 1-29-NH2 yields potent agonists and antagonists)


RN 243132-98-1 CAPLUS

CN L-Ornithinamide, N-methyl-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-alanyl-L-leucyl-L-glutamyl-D- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl-, (25-29)-lactam (9CI) (CA INDEX NAME)


NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KALQDIXSX


PAGE 1-A



PAGE 1-B



PAGE 1-C





RN 221377-49-7 CAPLUS  
CN D-Arginamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-norleucyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyll-L-leucyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNXY RKVLXQLSAR KLLQDIXSR

RN 221377-52-2 CAPLUS  
CN D-Arginamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl-(9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXSR

RN 221377-57-7 CAPLUS  
CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXSR

RN 221377-58-8 CAPLUS  
CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNRY RKVLXQLSAR KLLQDIXSR

RN 221377-59-9 CAPLUS  
CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-60-2 CAPLUS  
CN L-Lysinamide, N-(1-naphthalenylacetyl)-L-histidyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-76-0 CAPLUS  
CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-N6-(aminoiminomethyl)-L-lysyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-77-1 CAPLUS  
CN L-Lysinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoiminomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-78-2 CAPLUS  
CN L-Lysinamide, N-(1H-indol-3-ylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-

asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoininomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-79-3 CAPLUS

CN L-lysineamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-(aminoininomethyl)-L-lysyl-O-methyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoininomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

RN 221377-80-6 CAPLUS

CN L-lysineamide, N-(1-naphthalenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyl-L-arginyl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-D-arginyl-N6-(aminoininomethyl)- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXRR

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 23 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1998:597995 CAPLUS Full-text

DOCUMENT NUMBER: 130:25311

TITLE: Synthesis and in vitro biological activities of new potent GH-RH antagonists with citrulline substitutions

AUTHOR(S): Zarandi, Marta; Kovacs, Magdolna; Horvath, Judit E.;

Halmos, Gabor; Groot, Kate; Schally, Andrew V.

CORPORATE SOURCE: Endocrine, Polypeptide and Cancer Institute, Tulane

University, New Orleans, LA, 70146, USA

SOURCE: Peptides 1996, Proceedings of the European Peptide

Symposium, 24th, Edinburgh, Sept. 8-13, 1996 (

1998), Meeting Date 1996, 933-934. Editor(s):

Ramage, Robert; Epton, Roger. Mayflower Scientific:

Kingswinford, UK.

CODEN: 66RCAS

DOCUMENT TYPE: Conference

# LANGUAGE:

AB A symposium report on the preparation and gonadotropin hormone antagonistic

activity of citrulline-containing analogs.

IT 198404-49-8P 198404-52-3P 198404-55-6P

216368-91-1P 216368-98-8P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study), unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and biol. activities of new potent GH-RH antagonists with citrulline substitutions)

RN 198404-49-8 CAPLUS

CN L-Ornithinamide, N-(2-methyl-1-oxopropyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -

aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-

asparaginyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-(2S)-2-

aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-


leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-

seryl-N5-(aminocarbonyl)- (9CI) (CA INDEX NAME)


NTE modified

SEQ 1 YRDAIFTNRY RKVLXQLSAR KLLQDIXSX

PAGE 1-A






PAGE 1-B












RN 216368-91-1 CAPLUS  
 CN 1-29-Somatoliberin (human pancreatic islet), 2-[N5-(aminocarbonyl)-L-ornithine]-6-(4-chloro-L-phenylalanine)-15-[(2S)-2-aminobutanoic acid]-27-L-norleucine- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YXDAIFTNSY RKVLXQLSAR KLIQDIXSR





















U

RN 204866-79-5 CAPLUS  
CN L-Argininamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginyll-L-seryl-4-chloro-L-phenylalanyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl- (9CI) (CA INDEX NAME)  
NTE modified (modifications unspecified)  
SEQ 1 YRDAIFTNSF RKVLXQLSAR KLLQDIXSR

RN 204866-80-8 CAPLUS  
CN 1-29-Somatoliberin (human pancreatic islet), N-(phenylacetyl)-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-[(2S)-2-aminobutanoic acid]-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)  
NTE modified (modifications unspecified)  
SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXSR

RN 204866-81-9 CAPLUS  
CN 1-29-Somatoliberin (human pancreatic islet), N-(phenylacetyl)-2-D-arginine-6-(4-fluoro-L-phenylalanine)-15-[(2S)-2-aminobutanoic acid]-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)  
NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXSR

RN 204866-82-0 CAPLUS  
CN 1-29-Somatoliberin (human pancreatic islet), N-(phenylacetyl)-2-D-arginine-6-(4-iodo-L-phenylalanine)-15-[(2S)-2-aminobutanoic acid]-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)  
NTE modified (modifications unspecified)  
SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXSR

RN 204866-83-1 CAPLUS  
CN 1-29-Somatoliberin (human pancreatic islet), N-(phenylacetyl)-2-D-arginine-6-(4-chloro-L-phenylalanine)-10-(O-methyl-L-tyrosine)-15-[(2S)-2-aminobutanoic acid]-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)  
NTE modified (modifications unspecified)  
SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXSR

RN 204866-84-2 CAPLUS  
CN 1-29-Somatoliberin (human pancreatic islet), N-(phenylacetyl)-2-D-arginine-6-(4-iodo-L-phenylalanine)-10-(O-methyl-L-tyrosine)-15-[(2S)-2-aminobutanoic acid]-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)  
NTE modified (modifications unspecified)  
SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXSR

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 25 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1997:746077 CAPLUS Full-text  
DOCUMENT NUMBER: 127:359122  
TITLE: Preparation of hGH-RH(1-29)NH2 analogs having antagonistic activity

INVENTOR(S): Schally, Andrew V.; Zarandi, Marta; Toth, Katalin  
PATENT ASSIGNEE(S): Administrators of the Tulane Educational Fund, USA;  
SOURCE: Schally, Andrew V.; Zarandi, Marta; Toth, Katalin  
PCT Int. Appl., 52 pp.  
CODEN: PIXXD2

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO. ----- KIND DATE ----- APPLICATION NO. ----- DATE -----

WO 9742223 A1 19971113 WO 1997-US7452 19970502 <--  
 W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LX, LR, LS, LT, LU, LV, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RM: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DG, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG  
 US 5942489 A 19990824 US 1996-642472 19960503 <--  
 ZA 9703793 A 19971119 ZA 1997-3793 19970502 <--  
 AU 9731172 A 19971126 AU 1997-31172 19970502 <--  
 EP 914340 A1 19990512 EP 1997-926399 19970502 <--  
 EP 914340 B1 20030709  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI  
 JP 2001501385 T 20010206 JP 1997-540054 19970502 <--  
 CA 2253663 C 20020716 CA 1997-2253663 19970502 <--  
 CA 2253663 A1 19971113  
 AT 244731 T 20030715 AT 1997-926399 19970502 <--  
 PT 914340 T 20031128 PT 1997-926399 19970502 <--  
 ES 2200178 T3 20040301 ES 1997-926399 19970502 <--  
 US 1996-642472 A 19960503 <--  
 WO 1997-US7452 W 19970502 <--  
 PRIORITY APPLN. INFO.:  
 MARPAT 127:359122

OTHER SOURCE(S):  
 AB Title peptides X-R1-R2-R3-R4-R5-R6-Thr-R8-R9-R10-R11-R12 -Val-Leu-R15-Gln-Leu-Ser-R19-R20-R21-Leu-Gln-Asp-Ile-R27-R28-R29 [X = H, Ac, anthraquinone-2-carboxyl (Aqc), Iodoacetyl (Iac), bromopropionyl (BrProp), OHC, isobutyryl (Ibu), 1- or 2-naphthylacetyl (Nac), 1- or 2-naphthoyl (Npt), 1- or 2-naphthylpropionyl (Npr), phenylacetyl (PhAc), 3-phenylpropionyl (Epr), other aromatic or nonpolar acyl group: R1 = Tyr, His, Phe(Y); Y = H, F, Cl, Br, NO<sub>2</sub>, NH<sub>2</sub>, Me, OMe; R2 = D-Arg, D-Cit, D-Har, D-Lys, D-Tic, D-Orn, R3 = Asp, D-Asp, Ala, D-Ala, Gly; R4 = Ala, Abu, Gly; R5 = Ile, Ala, Gly, R6 = Phe, Tic, Ala, Pro, Tpi, Nal, Phe(Y); R8 = Asn, Gln, Ser, Thr, Val, Leu, Ile, Ala, D-Ala, D-Asn, D-Gln, D-Thr, D-Leu, Abu, D-Abu, Nle, Aib; R9 = Ser; R10 = Tyr or Phe(Y); R11 = Arg, D-Arg, Cit, R12 = Lys, D-Lys, Cit, D-Cit, Orn, D-Orn, Nle, Ala; R15 = Gly, Ala, Abu, Gln; R19 = Ala, Abu; R20 = Arg, D-Arg, Cit; R21 = Lys, D-Lys, Orn, Cit; R27 = Met, Nle, Abu; R28 = Ser, Asn, Asp, Ala, Abu; R29 = Arg, Arg-NH<sub>2</sub>, Arg-OH, Cit-NH<sub>2</sub>, Cit-OH, Har-NH<sub>2</sub>, Har-OH; Abu = 2-aminobutanoyl; Arg = agmatine, Cit = citrulline; Har = homoarginine, Nal = 2-naphthylalanine, Tic = 1,2,3,4-tetrahydroisoquinoline-2-carboxyl, Tpi = 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-3-carboxyl, and pharmaceutically acceptable salts thereof, are prepared and claimed as growth hormone release inhibitors and antitumor agents. Also claimed are cyclic peptides X-Al-B2-A3-R4-R5-R6-Thr-A8-Ser-R10-R11-B12-Val-Leu-R15-Al6-A17-Ser-R19-B20- B21-Leu-Leu-Gln-A25-Ile-R27-R28-B29 [X, R4, R5, R10, R15, R27, R28, = as above; A = Glu, D-Glu, Gln, Asp, D-Asp, Asn, Abu, Leu, Tyr, His, Phe(Y); Y = H, F, Cl, Br, NO<sub>2</sub>, Me, OMe, Ser, Thr, Val, Ile, Ala, D-Ala, D-Asn, D-Gln, D-Thr, D-Leu, Abu, D-Abu, Nle, Aib; B = Lys, D-Lys, Arg, D-Arg, Orn, D-Orn, Arg, R6 = Phe, Tic, Tpi, Nal, Phe(Y); Y = H, F, Cl, Br, NO<sub>2</sub>, Me, OMe], and pharmaceutically acceptable salts thereof, wherein a lactam bridge is formed between any pairs of positions 1,2; 2,3; 8,12; 16,20; 17-21, 21,25; 25,29; or both 8,12 and 21,25. Thus, peptide PhAc-Thr-D-Arg-Asp-Ala-Ile-Phe(Ic1)-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Abu-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Agm (I) was prepared by standard solid-phase methods on an aminomethyl resin using tert-butoxycarbonyl (Boc) Na-protection. I antagonized hGH-RH with K<sub>i</sub> = 0.0159 nM in an in vitro test, and in an antitumor test, treatment of 10 µg I per day resulted in significant inhibition of growth of SW-1990 tumors in nude mice.  
 IT 190783-58-5P 190783-59-6P 190791-06-1P  
 190791-08-3P 198404-49-8P 198404-52-3P


198404-55-6P 198404-60-3P 198404-67-0P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of human growth hormone releasing factor analogs having antagonistic activity)

RN 190783-58-5 CAPIUS  
 CN L-Argininamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-(2S)-2-aminobutanoyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-L-seryl- (9CI) (CA INDEX NAME)


NTE modified

SEQ 1 YRDAlFTXSY RKVLAQLSAR KLLQDIXSR

PAGE 1-A




PAGE 1-B










RN	190791-06-1	CAPLUS
CN	1-29-Somatoliberin (human pancreatic islet), N-(phenylacetyl)-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-L-alanine-27-L-norleucine-29-L-argininamide- (9CI)	(CA INDEX NAME)



NTE modified

SEQ 1 YRDAIFTNSY RKVLAQLSAR KLLQDIXSR


PAGE 1-A




PAGE 1-B




PAGE 2-B



PAGE 2-C











RN 190791-08-3 CAPLUS  
CN L-Argininamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-(2S)-2-aminobutanoyl-L-seryl-L-tyrosyl-L-arginyl-D-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyll-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-α-aspartyl-L-isoleucyl-L-norleucyl-L-seryl- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTXSY RKVLAQLSAR KLLQDIXSR











RN 198404-49-8 CAPLUS  
 CN L-Ornithinamide, N-(2-methyl-1-oxopropyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-L-asparaginy-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-L-seryl-N5-(aminocarbonyl)-(9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXSX






RN 198404-52-3 CAPLUS  
 CN L-Ornithinamide, N-(2-methyl-1-oxopropyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -  
 aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-(2S)-2-  
 aminobutanoyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-  
 aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-  
 leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-  
 seryl-N5-(aminocarbonyl)- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTXSY RKVLXQLSAR KLLQDIXSX








8

RN 198404-55-6 CAPLUS  
CN L-Ornithinamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-(2S)-2-aminobutanoyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-(2S)-2-aminobutanoyl-L-glutamyl-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L-α-aspartyl-L-isoleucyl-L-norleucyl-L-seryl-N5-(aminocarbonyl)-(9CI) (CA INDEX NAME)







NTE modified

SEQ 1 YRDAIFTXSY RKVLXQLSAR KILQDIXSX









L23 ANSWER 26 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1907:294814 CAPLUS Full-text  
DOCUMENT NUMBER: 127:29205

**TITLE:** Inhibition of GH release in rats by new potent antagonists of growth hormone-releasing hormone (GH-RH)

AUTHOR(S): Kovacs, Magdolna; Schally, Andrew V.; Zatandi, Marta; Groot, Kate

**CORPORATE SOURCE:** Endocrine, Polypeptide and Cancer Institute, Veterans Administration Medical Center and Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70146, USA

SOURCE: Orleans, LA, 70140, USA  
Peptides (Tarrytown, New York) (1997),  
18(3), 431-438

ISSN: 0196-9781  
CODEN: PPTDD5  
PTDD5: ISSN: 0196-9781

**PUBLISHER:**  
Elsevier

DOCUMENT TYPE: Journal  
LANGUAGE: English

Biol. activity of a new series of potent GH-RH antagonists containing formyl AB (D-Arg2, Phe(4-C1)6, Orn15, Nle27)hGHRH(1-29)-NH2, as well as various substitutions in positions 8, 15, or 28, and in some cases Argm in position 29, was evaluated *in vivo*. All five antagonists, administered at a 27-fold molar excess to rats, suppressed the GH-releasing effect of exogenous GH-RH(1-29)-NH2 by 64-75%. The inhibitory effects lasted for more than 15 min. The most potent analog, Phac-D-Arg2, Phe(4-C1)6, Orn15, Nle27)hGHRH(1-28)Argm (M2-5-156), showed an *in vivo* potency 7-16 times higher than the early antagonist [Ac-Tyr1, D-Arg2)hGHRH(1-29)-NH2, which was used as standard, M2-5-156 was capable of decreasing serum GH levels after *i.v.*, *i.p.*, or *i.m.* administration. *In vitro*, in the superfused rat pituitary cell system, M2-5-156 induced a prolonged inhibition of GH release after continuous long-term administration and showed a potency more than 100 times greater than the standard antagonist. These results show that N-terminal acylation with phenylacetic acid of the sequence (D-Arg2, Phe(4-C1)6, Nle27)hGHRH(1-29)-NH2, containing modification in positions 8, 15, 28, or 29, results in antagonists with high and protracted potency both *in vivo* and *in vitro*. In view of high antagonistic activity and prolonged duration of action, some of these antagonists of GH-RH may find clinical application for the treatment of IGF-dependent cancers.

IT 93942-91-7 190783-58-5 190783-59-6


RL: prp (Properties)  
(growth hormone release inhibition in rats by antagonists of growth hormone-releasing hormone)

RN	93942-91-7	CAPLUS
CN	1-29-Somatolibirin (human pancreatic islet), N-acetyl-2-D-arginine-29-L-argininamide- (9CI) (CA INDEX NAME)	


NTE modified

SEO 1 YRDAIF TNSY R KVLGOLSAR KLLODIMSR


PAGE 1-A




PAGE 1-B





PAGE 2-A





PAGE 2-C




RN 190783-58-5 CAPLUS

L-Argininsamide, N<sup>6</sup>-(phenylacetyl)-L-tyrosyl-D-arginyl-L- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-(2S)-2-aminobutanoyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminy-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-glutaminy-L- $\alpha$ -aspartyl-L-isoleucyl-L-norleucyl-L-seryl- (9CI) (CA INDEX NAME)

NTE modified



SEQ 1 YRDAIFTXSY RKVLAQLSAR KLLQDIXSR

PAGE 1-A









## REFERENCE COUNT:

30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L23 ANSWER 27 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1997:294702 CAPLUS Full-text

DOCUMENT NUMBER: 127:76139

TITLE: Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH)

AUTHOR(S): Zarandi, Marta; Kovacs, Magdolna; Horvath, Judit E.; Toth, Katalin; Halmos, Gabor; Groot, Kate; Nagy, Attila; Kele, Zoltan; Schally, Andrew V.

CORPORATE SOURCE: Endocrine, Polypeptide and Cancer Institute and Department of Medicine, Tulane University School of Medicine, New Orleans, LA, 70146, USA

SOURCE: Peptides (Tarrytown, New York) (1997), 18(3), 423-430  
CODEN: PPTDD5; ISSN: 0196-9781

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In the search for more potent antagonists of hGH-RH, 20 new analogs were synthesized, purified and tested in vitro. All the analogs were based on the N-terminal sequence of 28 or 29 amino acid residues of hGH-RH, but contained D-Arg2 and Nle27 modifications. Most analogs had Phe(pCl)6 and Argm29 substituents. The effect of other substitutions such as Abu8 and/or Abu15 and Ala15 and various hydrophobic and hydrophilic D or L amino acids at position 8 were also investigated. All the peptides were acylated at the N-terminus in an attempt to increase the antagonistic activity. In the superfused rat pituitary cell system, most analogs inhibited more powerfully the GH release induced by GH-RH than the standard antagonist (Ac-Tyr1, D-Arg2)hGH-RH (1-29)-NH2. Some antagonists were long acting. Among the peptides synthesized, antagonist PhAc-[D-Arg2, Phe(pCl)6, Abu1, Nle27]hGH-RH(1-26)Argm (M2-5-156) appeared to be the most potent and inhibited GH release in vitro 63-200 times more powerfully than the standard antagonist. M2-5-156 and other antagonists showed high binding affinities to membrane receptors for GH-RH. Some of these hGH-RH antagonists could be further developed for possible oncol. applications.

IT 93942-91-7 190783-58-5 190783-59-6

190791-06-1 190791-07-2 190791-08-3

190791-09-9

RL: BAC (Biological activity of effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)

(growth hormone-releasing hormone antagonist in vitro evaluation in relation to structure and receptor binding)


RN 93942-91-7 CAPLUS

CN 1-29-Somatoliberin (human pancreatic islet), N-acetyl-2-D-arginine-29-L-argininamide- (9CI) (CA INDEX NAME)







NTE modified

SEQ 1 YRDAIFTNSY RKVLGQLSAR KLLQDIMSR

PAGE 1-A








RN 190783-59-6 CAPLUS  
 CN L-Argininamide, N-(phenylacetyl)-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-(2S)-2-aminobutanoyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-leucyl-L-alanyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L-α-aspartyl-L-isoleucyl-L-norleucyl-(2S)-2-aminobutanoyl- (9CI)  
 (CA INDEX NAME)


NTE modified

SEQ 1 YRDAIFTXSY RKVLQLSAR KLLQDIXXR


PAGE 1-A




PAGE 1-B




PAGE 2-A






PAGE 2-B



PAGE 2-C









RN 190791-07-2 CAPLUS

CN L-Argininamidè, N-acetyl-L-tyrosyl-D-arginyl-L-α-aspartyl-L-alanyl-L-isoleucyl-4-chloro-L-phenylalanyl-L-threonyl-(2S)-2-aminobutanoyl-L-seryl-L-tyrosyl-L-arginyl-L-lysyl-L-valyl-L-leucyl-L-alanyl-L-glutaminyll-L-leucyl-L-seryl-L-alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutaminyll-L-α-aspartyl-L-isoleucyl-L-norleucyl-(2S)-2-aminobutanoyl- (9Ci) (CA INDEX NAME)

NTE modified




SEQ 1 YRDAIFTKSY RKVLAQLSAR KLLQDIXXR











L23 ANSWER 29 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1996:300265 CAPLUS Full-text

DOCUMENT NUMBER: 124:333537

TITLE: The inhibitory effects of growth hormone-releasing hormone (GHRH)-antagonist on GHRH, L-DOPA, and clonidine-induced GH secretion in normal subjects

Hanew, Kunihiko; Tanaka, Aki; Utsumi, Atsushi;

Sugawara, Akira; Abe, Keishi

AUTHOR(S):

CORPORATE SOURCE: Second Department Internal Medicine, Tohoku University

School Medicine, Sendai, 980, Japan

SOURCE: Journal of Clinical Endocrinology and Metabolism (

1996), 81(5), 1952-1955

CODEN: JCEMAZ; ISSN: 0021-972X

PUBLISHER: Endocrine Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB

The relative inhibitory potency of GHRH-Antagonist (GHRH-Ant) to GHRH(1-44)NH<sub>2</sub> and mechanism of L-DOPA- or clonidine-induced GH release were studied in seven normal subjects using GHRH-Ant. One hundred micrograms of GHRH-Ant (i.v. for 75 min) did not inhibit plasma GH responses to bolus injection of 100 µg and 10 µg GHRH or simultaneous infusion of 5 µg GHRH (i.v. for 75 min). However, 200 µg GHRH-Ant (i.v. for 75 min) significantly inhibited GH release, which was induced by simultaneous infusion of 5 µg GHRH. Although 100 µg GHRH-Ant could not significantly inhibit L-DOPA-induced GH release, 200 µg GHRH-Ant almost completely inhibited the response. Similarly, the same dose of GHRH-Ant markedly inhibited the GH-releasing activity of clonidine. It is concluded that the inhibitory potency of GHRH-Ant on GHRH(1-44)NH<sub>2</sub> is relatively weak (about 1/60 in molar base), and that L-DOPA- or clonidine-induced GH release seems to be mediated by the release of hypothalamic GHRH.

IT 93942-91-7

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(the inhibitory effects of growth hormone-releasing hormone

(GHRH)-antagonist on GHRH, L-DOPA, and clonidine-induced GH secretion


in normal subjects)

RN 93942-91-7 CAPLUS


CN 1-29-Somatoliberin (human pancreatic islet), N-acetyl-2-D-arginine-29-L-argininamide- (9CI) (CA INDEX NAME)

SEQ 1 YRDAIFTNSY RVLGQLSAR KLLQDIMSR


PAGE 1-A




PAGE 1-B




PAGE 2-A






PAGE 2-B



PAGE 2-C







L23 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1995:100215 CAPLUS Full-text  
 DOCUMENT NUMBER: 124:21956

TITLE:

**AUTHOR(S):** Hassan, Hazem A.; Hsiung, Hansen M.; Zhang, Xing-Yue; Smith, Dennis P.; Smiley, David L.; Heiman, Mark L.  
**CORPORATE SOURCE:** Div. Endocrinology, Eli Lilly and Co., Indianapolis,

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
84

**SOURCE:** Peptides (Tarrytown, New York) (1995),

16(8), 1469-73

CODEN: PPTBD5; ISSN: 0196-9781

PUBLISHER: Elsevier  
CODEN: TAPM

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To S

10<sup>6</sup> cells/ml, sealed, and stored at -80°C until use. The binding assay was developed using cloned porcine adenohypophyseal, GH-RH receptors expressed in human kidney 293 cells. Specific binding of [<sup>3</sup>H], [125I]-Tyr-D, [125I]-Tyr-D<sup>1</sup>-Nle<sup>27</sup> [D<sup>1</sup>]-GH-RH (1-32)-NH<sub>2</sub> increased linearly with protein concentration (10–45 µg protein/tube). Binding reached equilibrium after 90 min at 30°C and remained constant for at least 240 min. Binding was reversible to 1 class of high-affinity sites (K<sub>d</sub> = 104 nM, B<sub>max</sub> = 3.9 pmol/mg protein). Binding was selective with a rank order of affinity (IC<sub>50</sub>) for porcine GH-RH (2.8 nM), rat GH-RH (3.1 nM), [N<sup>6</sup>-Ac-Tyr-D, D<sup>1</sup>-Arg<sup>27</sup>]GH-RH (3-29)-NH<sub>2</sub> (3.9 nM), and [D<sup>1</sup>-Tyr<sup>27</sup>]GH-RH (1-29)-NH<sub>2</sub> (189.7 nM), consistent with their binding to GH-RH receptor. Nonhydrolyzable guanine nucleotides inhibited binding. These data describe a selective and reliable method for a competitive GH-RH binding assay that for the first time utilizes rapid filtration to terminate the binding assay.

IT 93942-91-7

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)


(characterization of growth hormone-releasing hormone binding to cloned porcine GH-RH receptor)

93942-91-7 CAPLUS

1-29-Somatoliberin (human pancreatic islet), N-acetyl-2-D-arginine-29-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified





L23 ANSWER 32 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1995:960194 CAPLUS Full-text  
 DOCUMENT NUMBER: 124:87800  
 TITLE: Preparation of analogs of human growth hormone releasing hormone hGH-RH(1-29)NH2 having antagonistic activity for hGH-RH  
 INVENTOR(S): Schally, Andrew V.; Zarandi, Marta  
 PATENT ASSIGNEE(S): Administrators of the Tulane Educational Fund, USA  
 SOURCE: PCT Int. Appl., 59 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9516707	A1	19950622	WO 1994-US13714	19941128 <--
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5550212	A	19960827	US 1993-168810	19931217 <--
CA 2178218	A1	19950622	CA 1994-2178218	19941128 <--
AU 9513322	A	19950703	AU 1995-13322	19941128 <--
AU 695315	B2	19980813		
EP 734396	A1	19961002	EP 1995-904767	19941128 <--
EP 734396	B1	20001108		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, NL, PT, SE				
ES 2152380	T3	20010201	ES 1995-904767	19941128 <--
PT 734396	T	20010430	PT 1995-904767	19941128 <--
ZA 9409641	A	19950825	ZA 1994-9641	19941205 <--
GR 3035170	T3	20010430	GR 2000-402857	20001229 <--
PRIORITY APPLN. INFO.:			US 1993-168810	A 19931217 <--
			WO 1994-US13714	W 19941128 <--
OTHER SOURCE(S):				
AB				

MARPAT 124:87800  
 Analogs of hGH-RH(1-29)NH2 having substitutions of various amino acids and acylated at the N-terminus X-R1-R2-R3-R4-R5-R6-Thr-R8-Ser-Tyr-R11-R12-Val-

Leu-R15-Gln-Leu-Ser-R19-R20-R21-Leu-Leu-Gln-Asp-Ile-R27-R28-R29 [X = nil, H, AC, ICH2CO, BrCH2CH2CO, CHO, Me2CHCH2CO, 1- or 2-naphthylacetyl, 1- or 2-naphthylpropionyl, anthraquinone-2-carbonyl; R1 = Tyr, His, Glu, glutaryl; R2 = D-Arg, D-Cit (citruilline), D-homoArg, D-Lys, D-Orn; R3 = Asp, Ala, Gly; R4 = Ala, Gly; R5 = Ile, Ala, Gly; R6 = Phe, Ala, Pro, 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid, 2-naphthylalanine, Phe(Y), in which Y = F, Cl, Br, NO2, Me, or OCH3; R8 is Asn, Ser, Val, Ile, Ala, Abu (α-aminoisobutyric acid), Nle, α-aminoisobutyric acid; R11 = Arg, D-Arg, Cit; R12 = Lys, D-Lys, Cit, Ala; R15 = Gly, Ala, Abu, Gln; R19 = Ala, Abu; R20 = Arg, D-Arg, Cit; R21 = Lys, D-Lys, Cit; R27 = Met, Nle, Abu; R28 = Ser, Asn, Asp, Abu; R29 = agmatine, Arg-NH2, Arg-OH, Cit-NH2, Cit-OH, homoArg-NH2, homoArg-OH; provided that when R1 is glutaryl, X is nil and when X is H, R15 is other than Gly] and pharmaceutically acceptable acid addition salts thereof, which inhibit the release of hGH from the pituitary in mammals and exhibit prolonged antagonistic activity, are prepared. Thus, Nac-Tyr-D-Asp-Ala-Ile-Phe(p-Cl)-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Abu-Gln-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Nle-Ser-Agm-OH (I; Nac = 1-naphthylacetyl, Agm = agmatine) was prepared by the solid phase method using Boc-Agm-SPA-aminomethyl resin (California Peptide Co.) and N-Boc-protected amino acids and acylation of the resin-bound peptide with 1-naphthylacetic anhydride on the NH2 group of Tyr. I in vitro at 30 nM inhibited the GH release from rat superfused pituitary system by 96, 98, and 48% 2, 4.5, and 6 h after the incubation, resp.

IT 160361-93-3P 160361-94-4P 160361-95-5P

160499-35-4P 160499-40-1P 171047-66-8P

171047-67-9P 171047-68-0P 171047-69-1P






RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PRP (Preparation); USES (Uses) (preparation of human growth hormone releasing hormone (hGH-RH) analogs as hGH-RH antagonists and inhibitors of hGH release from pituitary gland)

RN 160361-93-3 CAPLUS

CN 1-29-Somatoliberin (human pancreatic islet), 1-(N-acetyl-L-histidine)-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-(L-2-aminobutanoic acid)-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)




NTE modified

SEQ 1 HRDAIFTNSY RKVLXOLSAR KLLQDIXSR









160499-35-4 CAPTUS  
1-29-Somatoliberin (human placental islet), 1-[N-(1-naphthalenylacetyl)-L-histidine]-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-(L-2-aminobutanoic acid)-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

1 HRDAIFTNSY R KVLXOLSAR KLLQDIXSR

160499-40-1 CAPLUS  
1-29-Somatolibarin (human pancreatic islet, N-(1-naphthalenylacetyl)-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-(L-2-aminobutanonic acid)-27-(L-norleucine-29-L-argininamide-19CI) (CA INDEX NAME)



NTE modified (modifications unspecified)

1 YRDAIFTNSY R KVLXQLSAR KLLQDIXSR  
SEQ

171047-66-8 CAPLUS  
1-29-Somatolibirin (human pancreatic islet), N-(2-methyl-1-oxopropyl)-2-D-  
arginine-8(2-methylalanine)-15-(1-2-aminobutanoic acid)-27-1-norleucine-  
29-1-argininamide- (9CI) (CA INDEX NAME)

NTE modified




1 YRDAIFTXSY RKVLXQLSAR KLLQDIXSR













RN 171047-69-1 CAPLUS  
 CN 1-29-Somatoliberin (human pancreatic islet), N-(2-methyl-1-oxopropyl)-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-(L-2-aminobutanoic acid)-19-(L-2-aminobutanoic acid)-27-L-norleucine-29-L-argininamide- (9CI)  
 (CA INDEX NAME)


NTE modified

SEQ 1 YRDAIFTNSY RKVLXOLSXR KLLQDIXSR


Absolute stereochemistry.




PAGE 2-B



PAGE 3-A



PAGE 3-B



L23 ANSWER 33 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 1995:259031 CAPLUS Full-text  
 122:96644  
 TITLE:  
 Synthesis and biological activities of highly potent  
 antagonists of growth hormone-releasing hormone

## AUTHOR (S):

Zarandi, M.; Horvath, J. E.; Halmos, G.; Pinski, J.;  
 Nagy, A.; Groot, K.; Rekasi, Z.; Schally, A. V.  
 Vet. Affairs Med. Cent., Tulane Univ. Sch. Med., New  
 Orleans, LA, 70146, USA  
 Proceedings of the National Academy of Sciences of the  
 United States of America (1994), 91(25),  
 12298-302

## CORPORATE SOURCE:

## SOURCE:

CODEN: PNASAF; ISSN: 0027-8424  
 National Academy of Sciences  
 Journal  
 English

## PUBLISHER:

## DOCUMENT TYPE:

## LANGUAGE:

## AB

In the search for antagonists of human growth hormone-releasing hormone (hGHRH) with high activity, 22 analogs were synthesized by solid-phase methods, purified, and tested biol. Within the N-terminal sequence of 28 or 29 amino acids of hGHRH, all the analogs contained D-Arg2, Phe(4-Cl)6 (para-chlorophenylalanine), Abu15 ( $\alpha$ -aminobutyric acid), and Nle27 and most of them had Arg29 (agmatine) substituents. All the peptides, except one, were acylated at the N terminus with different hydrophobic acids-e.g., isobutyric acid (Ibu) or 1-naphthylacetic acid (Nac) to study the effect of N-terminal acylation on the antagonistic activity. In the superfused rat pituitary cell system, all the analogs inhibited more powerfully the GHRH-induced growth hormone (GH) release than the standard GHRH antagonist [Ac-Tyr1, D-Arg2]hGHRH-(1-29)NH2. Antagonists [Ibu9, D-Arg2, Phe(4-Cl)6, Abu15, Nle27]hGHRH-(1-28)Agm (M2-4-71), [Nac10, D-Arg2, Phe(4-Cl)6, Abu15, Nle27]hGHRH-(1-29)NH2 (M2-4-169), [Nac10, D-Arg2, Phe(4-Cl)6, Abu15, Nle27]hGHRH-(1-29)NH2 (M2-4-181), and [Nac10, D-Arg2, Phe(4-Cl)6, Abu15, Nle27, Asp28]hGHRH-(1-28)Agm (M2-4-243) inhibited GH release at 3+10-9 M. Among these peptides, M2-4-243, M2-4-169, and M2-4-181 were also long acting in vitro. Antagonist M2-4-243 inhibited GH release 100 times more powerfully than the standard antagonist and was the most potent in vitro among GHRH antagonists synthesized. Analogs with high inhibitory effects in vitro were also found to have high affinities to rat pituitary GHRH receptors. In expts. in vivo, antagonists [Ibu0, D-Arg2, Phe(4-Cl)6, Abu15, Nle27]hGHRH-(1-28)Agm (M2-4-71), [Nac0, D-Arg2, Phe(4-Cl)6, Abu15, Nle27]hGHRH-(1-29)NH2 (M2-4-169), and [Nac0, His1, D-Arg2, Phe(4-Cl)6, Abu15, Nle27]hGHRH-(1-29)NH2 (M2-4-181) induced a significantly greater inhibition of GH release than the standard antagonist. In view of their high antagonistic activity and prolonged duration of action, some of these antagonists of GHRH may find clin. applications, including treatment of certain endocrine disorders and insulin-like growth factor I-dependent tumors.

## IT

160361-93-3 160361-94-4 160361-95-5  
 160499-35-4 160499-40-1

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)  
 (synthesis and biol. activities of highly potent antagonists of growth hormone-releasing hormone)

## RN

160361-93-3 CAPLUS

## CN

1-29-Somatoliberin (human pancreatic islet), 1-(N-acetyl-L-histidine)-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-(L-2-aminobutanoic acid)-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)

## NTE modified

SEQ 1 HRDAIFTNSY RKVLXOLSAR KLLQDIXSR



PAGE 3-A




RN 160361-94-4 CAPLUS  
CN 1-29-Somatoliberin (human pancreatic islet), 1-[N-(2-methyl-1-oxopropyl)-L-histidine]-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-(L-2-aminobutanoic acid)-27-L-norleucine-29-L-argininamide- (9Ci) (CA INDEX NAME)


NTE modified

SEQ 1 HRDAITNSY RKVLXQLSAR KLLQDIXSR


PAGE 1-A




PAGE 1-C




PAGE 1-D




PAGE 2-B




PAGE 2-C




PAGE 2-D



PAGE 3-A



PAGE 3-B




160361-95-5	CAPLUS
1-29-Somatoliberin (human pancreatic islet, 1-(N-(iodoacetyl)-L-histidinyl-2-D-arginine-6-(4-chloro-1-phenylalanine)-15-(L-2-aminobutanoic acid)-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)	


NTE modified






SEQ 1 HRDAIFTNSY R KVLXQLSAR KLLQDIXSR

PAGE 1-A



PAGE 1-D


$$\begin{array}{c} \text{CH}_2\text{-OH} \\ | \\ \text{O}=\text{C}-\text{NH}-\text{CH}-\text{C}(=\text{O})-\text{NH}-\text{CH}-\text{C}(=\text{O})-\text{NH}-\text{CH}-\text{C}(=\text{O})-\text{NH}_2 \\ | \quad | \quad | \quad | \quad | \\ \text{Bu-n} \quad \text{Me} \quad \text{Et} \quad \text{CH}_2-\text{CO}_2\text{H} \end{array}$$



RN 160499-35-4 CAPLUS

1-29-Somatoliberin (human pancreatic islet), 1-[N-(1-naphthalenylacetyl)-L-histidine]-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-(L-2-aminobutanoic acid)-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 HRDAIFTNSY R KVLXQLSAR KLLQDIXSR

RN 160499-40-1 CAPLUS

100499-40-1 CAFL03  
1-29-Somatoliberin (human pancreatic islet), N-(1-naphthalenylacetyl)-2-D-arginine-6-(4-chloro-L-phenylalanine)-15-(L-2-aminobutanoic acid)-27-L-norleucine-29-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified (modifications unspecified)

SEQ 1 YRDAIFTNSY RKVLXQLSAR KLLQDIXSR

123 ANSWER 34 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:293308 CAPLUS Full-text

DOCUMENT NUMBER: 120:293308

**TITLE:** Amino acid identification and sequence analysis of

peptides by reaction mass spectrometry

**AUTHOR(S):**  
Yang, Huijun; Hu, Xiaoyu; Chen, Yaoyu

CORPORATE SOURCE: State Key Lab. Appl. Org. Chem., Lanzhou Univ., Lanzhou, China.

Lanzhou, 730000, Peop. Rep. China

SOURCE: Chinese Journal of Chemistry (1993), 11(6),

540-9

CODEN: CJOCEV; ISSN: 1001-604X

188

## DOCUMENT TYPE:

Journal  
English

## LANGUAGE:

AB Fast-atom-bombardment mass spectrometry (FAB-MS) is used to distinguish N-terminal series ions from C-terminal series ions of a peptide by on-probe acetylation, and it provides valuable information about the sequence of an unknown peptide. The FAB mass spectra contain a number of characteristic ions in the low-mass region in addition to the sequence ions in the high-mass region. The ions below  $m/z$  200 are characteristic of the amino acid composition of the peptide, from which the amino acid composition of the peptide could be estimated. Mixture anal. also is discussed.

IT 121282-52-8

RL: PRP (Properties)

(sequence of, determination of, by fast-atom-bombardment mass spectrometry)


RN 121282-52-8 CAPLUS

CN Somatolibirin (human pancreatic islet), 2-L-arginine-29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)


NTE modified

SEQ 1 YRDAIFTNSY RKVLGQLSAR KLLQDIMSR


PAGE 1-A




PAGE 1-B




PAGE 2-A




PAGE 2-B



PAGE 2-C





L23 ANSWER 35 OF 49 CAPLUS COPYRIGHT 2007 ACS on STM

ACCESSION NUMBER: 1993:420652 CAPLUS Full-text

DOCUMENT NUMBER: 119:20652

TITLE: Position 2 and position 2/Ala15-substituted analogs of bovine growth hormone-releasing factor (bGRF) with enhanced metabolic stability and improved in vivo bioactivity

AUTHOR(S): Kubiak, Teresa M.; Friedman, Alan R.; Martin, Roger A.; Ichihpurani, Amreet K.; Alaniz, Glenn R.; Claflin, William H.; Goodwin, Martha C.; Cleary, Diane L.; Kelly, Colleen R.; et al.

CORPORATE SOURCE: Upjohn Co., Kalamazoo, MI, 49001, USA

SOURCE: Journal of Medicinal Chemistry (1993), 36(7), 888-97

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To prepare GRF analogs with high activity in vivo, a strategy was undertaken to stabilize the peptide to dipeptidylpeptidase IV (DPP-IV), a protease found in plasma which inactivates native human and bovine GRF by cleavage of the Ala2-Asp3 bond. Replacement of the Ala2 residue with Ser, Thr, or Gly in [Leu27]bGRF(1-29)NH2 resulted in peptides greatly stabilized against proteolysis in plasma, but having low inherent GH-releasing activity when tested in bovine pituitary cell cultures. Replacement of Gly15 with Ala15 was marginally effective in improving the in vitro bioactivity of this group of peptides. When tested for GH-hormone release in steers, however, the Thr2,Ala15 analog was four times more potent than bGRF(1-44)NH2. Eleven additional analogs from the [X2,Ala15,Leu27]bGRF(1-29)NH2 series were synthesized and evaluated for metabolic stability in bovine plasma and for GH releasing activity in steers in vivo and in rat pituitary cells in vitro. Two compounds, [Val2,Ala15,Leu27]bGRF(1-29)NH2 and [Ile2,Ala15,Leu27]bGRF(1-29)NH2, had increased GH-releasing activity in steers over that of [Thr2,Ala15,Leu27]bGRF(1-29)NH2 and over a previously reported super-potent analog, [desNH2Tyr1,D-Ala2,Ala15]bGRF(1-29)NH2.

IT 148298-15-1

RL: BIOL (Biological study)

(growth hormone-releasing activity and biol. stability of, structure in relation to)


RN 148298-15-1 CAPLUS

CN Somatoliberin (human pancreatic islet), 2-L-arginine-15-L-alanine-27-L-leucine-28-L-asparagine-29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)


NTE modified

SEQ 1 YRDRIFTNSY RKVLAQLSAR KLLQDILNR


PAGE 1-A







PAGE 1-B



PAGE 2-A





L23 ANSWER 36 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1993:401079 CAPLUS Full-text  
 DOCUMENT NUMBER: 119:1079

TITLE: A method for evaluation of activity of antagonistic  
 analogs of growth hormone-releasing hormone in a  
 superfusion system

AUTHOR(S): Rekasi, Zoltan; Schally, Andrew V.  
 CORPORATE SOURCE: Med. Sch., Tulane Univ., New Orleans, LA, 70146, USA  
 SOURCE: Proceedings of the National Academy of Sciences of the  
 United States of America (1993), 90(6),

2146-9  
CODEN: PNASA6; ISSN: 0027-8424

## DOCUMENT TYPE:

LANGUAGE: English

AB To evaluate the endocrine effect of GH-releasing hormone (GHRH) antagonists, a sensitive dynamic *in vitro* system was developed. The concentration causing 50% inhibition (IC50) of the standard GHRH antagonist human [N-Ac-Tyr<sup>1</sup>, D-Arg<sup>2</sup>]GHRH-(1-29)-NH<sub>2</sub> is 4.5 + 10<sup>-8</sup>M in the dispersed pituitary cell superfusion system. This value is 11-fold less than that measured in earlier static pituitary cell cultures. This reliable dynamic system is simple, fast and inexpensive and not only makes it possible to obtain quant. data on the inhibitory capacity of the antagonists but also provides information about the intrinsic GHRH activity of the analog. The dynamic interacting of the GHRH antagonist, the GHRH receptors, and GH release can also be evaluated by this superfusion system. The pulsatile GH release induced by 10<sup>-9</sup>M human GHRH-(1-29)-NH<sub>2</sub> was inhibited by 2 modes of application, preincubation and simultaneous administration of the GHRH antagonist (10<sup>-9</sup>-10<sup>-6</sup>M). The reduction in GHRH-stimulated GH response was more pronounced when the cells were preincubated with the antagonist prior to GHRH infusion than for simultaneous application. The inhibitory effect of the antagonist was dose-dependent, temporary, and of the competitive type. GH release induced by nonspecific stimulus (100 mM KCl) was not influenced by the GHRH antagonist. This sensitive dynamic *in vitro* system appears to be a suitable method for screening the biol. activity of various GHRH antagonists and eliminates the drawbacks of static pituitary cell culture.

II

RL: ANST (Analytical study)  
(somatoliberin antagonistic activity of, method for evaluation of, in  
superfusion system of anterior pituitary cells)


RN

1-29-Somatoliberin (human pancreatic islet), N-acetyl-2-D-arginine-29-L-argininamide- (9CI) (CA INDEX NAME)


NTE modified

SEQ 1 YRDAIFTNSY RKVLGQLSAR KLLQDIMSR


PAGE 1-A




PAGE 1-B








PAGE 2-A



PAGE 2-B








138659-25-3 CAPLUS  
Somatoliberin (human pancreatic islet), 2-D-arginine-8-L-alanine-15-L-alanine-29-L-arginamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTASY RKVLAQLSAR KLLQDIMSR








138659-26-4 CAPIJUS  
Somatolibirin (human pancreatic islet), 2-D-arginine-8-L-alanine-9-L-alanine-15-L-alanine-25-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide-(9C1) (CA INDEX NAME)

NTE modified


SEQ 1 YRDAIFTAAY RKVLAQLSAR KLLQDMSR



PAGE 2-A



PAGE 2-B





















RN 121282-56-2 CAPLUS  
CN Somatolibexin (human pancreatic islet), 2-D-arginine-8-D-asparagine-15-L-alanine-29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI)  
(CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTNSY RKVLAQLSAR KLLQDIMSR







121396-16-5 CAPLUS  
Somatolibrin (human pancreatic islet), N-acetyl-2-D-arginine-29-D-arginine-30-L-argininamide-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-alanine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)

NT modified

1 YRDAIFTNSY RKVLGOLSAR KLLQDIMSRR  
1 SEO

121396-17-6 CAPLUS  
Somatoliberin (human pancreatic islet), 2-D-arginine-29-D-arginine-30-L-tyrosinamide-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)

NOTE modified

1 YRDAIETNSY RKVIGOLISAR KKLODIMSBRY

URN	12148-26-8	CAPLUS	Somatoliberin (human pancreatic islet), 2-D-arginine-	(9CI)	(CA INDEX NAME)
CN					

NTF modified

1 YRDAIFTNSY R KVLGOLSAR KLLODIMSRO OGESNOERGA RARL  
SE0


126883-97-4 CAPLUS  
L-Arginamide, L-tyrosyl-D-arginyl-D- $\alpha$ -aspartyl-L-alanyl-L-isoleucyl-L-phenylalanyl-L-threonyl-D-asparagyl-L-seryl-D-tyrosyl-D-isoleucyl-L-valyl-L-leucyl-L-alanyl-L-glutamyl-L-leucyl-L-seryl-L-

alanyl-L-arginyl-L-lysyl-L-leucyl-L-leucyl-L-glutamyl-L- $\alpha$ -aspartyl-L-isoleucyl-L-methionyl-L-seryl- (9CI) (CA INDEX NAME)


NTE modified

SEQ 1 YRDAIFTNSY RKVLAQLSAR KLLQDIMSR


PAGE 1-A




PAGE 1-B




PAGE 2-A




PAGE 2-B






PAGE 2-C





126803-98-5 CAPTUS  
Somatolibin (human pancreatic islet), 2-D-arginine-29-D-arginine-30-de-L-  
CN glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic  
acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic  
acid-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-  
arginine-44-de-L-leucinamide-9(CI) (CA INDEX NAME)


SEQ 1 YRDAIFTNSY RKVLGQLSAR KLLQDIMSRR


















RN 121202-52-8 CAPLUS  
CN Somatoliberin (human pancreatic islet), 2-L-arginine-29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9C1) (CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTNSY RKVLQQLSAR KLLQDMSR







RN 121396-17-6 CAPLUS  
CN Somatoliberin (human pancreatic islet), 2-D-arginine-29-D-arginine-30-L-tyrosinamide-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTNSY RKVLGOLSAR KLLQDIMSRY

L23 ANSWER 40 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1989:433758 CAPLUS Full-text

DOCUMENT NUMBER: 111:33758  
TITLE: Structure-activity relations of growth

hormone-releasing factor (GRF)

AUTHOR(S): Sato, Kazuki; Hotta, Mari; Kageyama, Jingo; Chiang,

Teh Chang; Hu, Hsiao Yu; Dong, Ming Hui; Ling,

Nicholas

CORPORATE SOURCE: Salk Inst., La Jolla, CA, 92037, USA

SOURCE: Peptide Chemistry (1989), Volume Date 1988,

26th, 85-90

CODEN: PECHDP; ISSN: 0388-3698

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cyclic analogs of human growth hormone-releasing factor (hGRF) (1-29)NH<sub>2</sub>, known to retain most of the bio activity of the native mol., were synthesized and intrinsic activities and antagonist potencies compared by using a rat anterior pituitary cell culture. The hGRF(1-29)NH<sub>2</sub> analogs contained cyclic modifications as follows: Cys2 linked to Cys15, Cys3 to Cys14, Cys4 to Cys13, Cys5 to Cys15, Cys2 to Cys13 and Cys5 to Cys14. All the analogs were weak agonists. Analogs (28) were prepared with a corresponding D-amino acid at each position of hGRF(1-29)NH<sub>2</sub>, except for glycine at position 15. Analogs with D-Ile5, D-Phe6, D-Thr7, and D-Val13 were much less potent than hGRF(1-29)NH<sub>2</sub>, suggesting that the specific conformation of these positions is important for the binding of the analogs to the hGRF receptor. Since [D-Arg7]hGRF(1-29)NH<sub>2</sub> had low intrinsic activity and some antagonistic activity,

a series of similarly modified analogs of rat GRF were prepared. The N-terminally acetylated analog ([N-Ac-Tyr<sup>1</sup>,D-Arg<sup>2</sup>]hGRF(1-29)NH<sub>2</sub>) was a more effective antagonist than [D-Arg<sup>2</sup>]hGRF(1-29)NH<sub>2</sub>, because it showed lower intrinsic activity than the [D-Arg<sup>2</sup>]peptide. The [D-Arg<sup>2</sup>,D-Asn<sup>8</sup>,Ala<sup>15</sup>] analog had higher antagonistic potency than [D-Arg<sup>2</sup>]hGRF(1-29)NH<sub>2</sub>; however, it also had higher intrinsic activity. [D-Arg<sup>2</sup>,29,Arg<sup>30</sup>]hGRF(1-30)NH<sub>2</sub> was the most potent antagonist in the hGRF series. In the rat series [N-Ac-His<sup>1</sup>,D-Arg<sup>2</sup>,Ala<sup>15</sup>]hGRF(1-29)NH<sub>2</sub> was the most potent antagonist. These compounds were prepared studied on part of a search for specific antagonists of hGRF for clin. and research uses.

IT 93942-91-7 93942-95-1 121282-52-8

121282-56-2 121282-57-3 121282-58-4

121396-16-5 121396-17-6 121396-19-8

121448-26-8

RL: PRP (Properties)

(structure-somatoliberin activity relation of)


RN 93942-91-7 CAPTUS

CN 1-29-Somatoliberin (human pancreatic islet), N-acetyl-2-D-arginine-29-L-argininamide- (9CI) (CA INDEX NAME)


NTE modified

SEQ 1 YRDAIFTNSY RKVLQLSAR KLLQDIMSR


PAGE 1-A




PAGE 1-B




PAGE 2-A




PAGE 2-B



PAGE 2-C












RN 93942-95-1 CAPLUS  
CN Somatoliberin (human pancreatic islet), 2-D-arginine-29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTNSY RKVLGQLSAR KLLQDINSR













RN 121282-56-2 CAPLUS  
CN Somatoliberin (human pancreatic islet), 2-D-arginine-8-D-asparagine-15-L-alanine-29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI)  
(CA INDEX NAME)

NTE modified

SEQ 1 YRDRIFTNSY RKVLAQLSAR KLLQDIMSR






RN 121282-57-3 CAPLUS

CN Somatoliberin (human pancreatic islet), N-acetyl-2-D-arginine-8-D-  
asparagine-15-L-alanine-29-L-argininamide-30-de-L-glutamine-31-de-L-  
glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-  
asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-  
deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-  
arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTNSY RKVLAQLSAR KLLQDIMSR











RN 121282-58-4 CAPLUS  
 CN Somatoliberin (human pancreatic islet), 2-D-arginine-29-D-arginine-30-L-argininamide-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDAIFTNSY RKVLGQLSAR KLLQDMSRR





RN	CN	
121386-16-5	CAPLUS	Somatolibrin (human pancreatic islet), N-acetyl-L-2-D-arginine-29-D-arginine-30-L-argininamide-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide (9CT) (CA INDEX NAME)

NTE modified

1 YRDAIFTNSY RKVLGOLSAR KLLQDIMSRR

121396-17-6 CAPIUS  
Somatoliberin (human pancreatic islet), 2-D-arginine-29-D-arginine-30-L-tyrosinamide-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-

CA INDEX NAME	(9CI)	(CA INDEX NAME)
L-alanine-43-de-L-arginine-44-de-L-leucinamide-		

NTE modified

SEQ 1 YRDAIFTNSY R KVLGQLSAR KLLQDIMSRY

RN 121396-19-8 CAPLUS

123550-23-0 CN Somatostatin (human pancreatic islet), N-acetyl-2-D-arginine-29-D-arginine-30-L-tyrosinamide-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9ci) (CA INDEX NAME)

NTE modified

SEO 1 YRDAIFTNSY RKVLGOLSAR KLLODIMSR

RN 121448-26-8 CAPLUS

AN	121770	20	0	CA1200	
CN	Somatoliberein (human pancreatic islet), 2-D-arginine-			(9CI)	(CA INDEX NAME)

NTE modified

SEO 1 YRDAIFTNSY R KVLGOLSAR KLLODIMSRO QGESNOERGA RARL

L23 ANSWER 41 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

E23 ANSWER 41 OF 43 CAPLUS COPYRIGHT 2007 ACS ON SITE  
 ACCESSION NUMBER: 1989:166384 CAPLUS Full-text

ACCESSION NUMBER: 1203:10650  
DOCUMENT NUMBER: 110:166384

DOCUMENT NUMBER: 110-10004

TITLE: Blockade of growth hormone-releasing factor (GRF)

activity in the pituitary and hypothalamus o

activity in the preoptic and hypothalamic conscious rat with a peptidic GRF anta

AUTHOR(S) :

AUTHOR(S):  
CORPORATE SOURCE:

CORPORATE SOURCE:  
Sch. Med., Georgetown Univ., Washington, DC, 20007,  
USA

SOURCE: USA  
Endo

SOURCE: Endocrinology (1989), 124(3), 1522-31  
CODEN: ENDOAO; ISSN: 0013-7227



CODEN: ENDOAQ; ISSN: 0013-1227  
Journal  
DOCUMENT TYPE.

DOCUMENT TYPE: Journal  
LANGUAGE: English

**LANGUAGE:** English

**AB** Microinjection of synthetic growth hormone-releasing factor (GRF) into the cerebrotentrioles or hypothalamus of the rat produces a number of neural effects, including the suppression of growth hormone (GH) secretion, possibly representing a neg. ultrashort loop autoregulation of GRF and/or stimulation of somatostatin neurosecretion. To demonstrate that such neuromodulation acts physiologically through endogenous GRF activity, the peptidic GRF antagonist (N-Ac-Tyr<sup>1</sup>, D-Arg<sup>2</sup>)/GRF-(1-29)-NH<sub>2</sub> was used to block the action of GRF on its presumed receptors in the hypothalamus. First, to establish the efficacy of the antagonist to block GRF receptors in the anterior pituitary, the antagonist was injected i.v. at doses of 2,220, and 50 µg into conscious male rats fitted with jugular cannulae. Sequential blood sampling every 15 min for 6 h between 1000-1600 h showed that 50 µg antagonist, i.v., suppressed the 2 periods of spontaneous release of RIAble GH in controls in the morning and afternoon. A dose of 20 µg, i.v., lowered mean plasma GH between 1400-1500 h,





L23 ANSWER 42 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1989:148244 CAPLUS Full-text

DOCUMENT NUMBER: 110:148244

TITLE: Inhibition of pulsatile growth hormone (GH) secretion

and somatic growth in immature rats with a synthetic

GH-releasing factor antagonist

Lumpkin, Michael D.; Mulrone, Susan E.; Haramati,

Aviad

Sch. Med., Georgetown Univ., Washington, DC, 20007,

USA

SOURCE: Endocrinology (1989), 124(3), 1154-9

CODEN: ENDO; ISSN: 0013-7227

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Indwelling Silastic catheters were placed into the jugular veins of immature

male rats (120-140 g) at 29 days of age. After a recovery period of 48 h,

beginning at 1000 h, 100-400 µg (N-Ac-Tyr1,D-Arg2)growth hormone-releasing

factor-(1-29)-NH<sub>2</sub> (GRF antagonist)/kg or its vehicle (controls) were injected i.v. immediately after withdrawing an initial blood sample from conscious undisturbed animals. Subsequent samples were obtained every 20 min until 1520 h. Red blood cells were resuspended in a restorative volume of saline and reinjected after each blood sample. Both doses of antagonist prevented the 2 major periods of episodic growth hormone (GH) release observed in controls. For example, mean plasma GH (nanograms per mL) at 1120 h was 9.0 in antagonist-treated rats and 37.1 in controls. Mean plasma GH at 1340 h was 10.8 in antagonist-treated rats and 38.8 in controls. Injection of 400 µg/kg of the structurally related VIP antagonist (N-Ac-Tyr1,D-Phe2)GRF-(1-29)-NH<sub>2</sub>, i.v. failed to suppress spontaneous GH release. GRF antagonist (100 µg/kg) was next administered twice daily i.v. for 4 days to 31-day-old rats in metabolic cages. This treatment essentially arrested the normal rapid body weight gain, significantly suppressed increases in body and tail lengths, and reduced increases in heart and kidney wts. Food intake and fecal output were unchanged by antagonist treatment and, therefore, did not contribute to the observed effects. Apparently, a number of tissues and organs are stimulated by the pulsatile secretion of GH and a peptidic GRF receptor antagonist is useful in blocking episodic GH release in immature animals. As a consequence, this specific antagonist is effective in suppressing numerous aspects of somatic growth.

IT 93942-91-7

RL: BIOL (Biological study)


(growth and somatotropin secretion inhibition by)






RN 93942-91-7 CAPLUS

CN 1-29-Somatoliberin (human pancreatic islet), N-acetyl-2-D-arginine-29-L-argininamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDIAFTNSY RKVLGOLSR KLLQDIMSR





123 ANSWER 43 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1988:48562 CAPLUS Full-text  
 DOCUMENT NUMBER: 109:48562  
 TITLE: Synthesis and in vitro bioactivity

**TITLE:** Synthesis and in vitro bioactivity of human growth hormone-releasing factor analogs substituted with a single D-amino acid

**AUTHOR(S):** Sato, Kazuki; Hotta, Mari; Kageyama, Jingo; Chiang, Teh Chang; Hu, Hsiao Yu; Dong, Ming Hui; Ling, Nicholas

AUTHOR(S) :



CORPORATE SOURCE:

**SOURCE:**

DOCUMENT TYPE:  
Journal  
LANGUAGE:  
English  
CODEN: BBRCA9; ISSN: 0006-291X







L23 ANSWER 44 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1987:576483 CAPLUS Full-text  
 DOCUMENT NUMBER: 107:176483  
 TITLE: (N,N'-dialkylguanidino)amino acyl GRF analogs  
 INVENTOR(S): Nestor, John J.  
 PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA  
 SOURCE: U.S., 11 pp. Cont.-in-part of U.S. Ser. No. 605,346, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US '4659693	A	19870421	US 1985-707007	19850228

PRIORITY APPLN. INFO.:  
 GI

US 1984-605346

A2 19840430 &lt;--

R1-R2-R3-R4-Ile-Phe-Tyr-R8-Ser-R10-Arg-R12-  
 R13-Leu-R15-Gln-Leu-R18-Ala-Arg-Lys-Leu-  
 Leu-R24-R25-Ile-R27-R28-Arg-Gln-Gln-  
 Gly-Glu-R34-Asn-Gln-Glu-R38-R39-  
 R40-R41-R42-Thr-R43-R44



AB The title compds. [I; R1 = H, D- or L-H-Tyr, N-methyltyrosyl, His, R2, excluding D- or L-Ala and D- or L-Leu; R2 = D- or L-Ala, D- or L-Leu, Q, where n = 1-5; S1 = alkyl, etc.; S2 = H; S1C(NS2) = 5H-imidazol-2-yl, etc.; R3 = Asp, Asn, Glu; R4 = Ala, Gly; R8 = Asn, Ser; R11 = D-Tyr, Phe; R12 = Lys, Arg; R13 = Ile, Val; R15 = Gly, D-Ala; R18 = Ser, Tyr; R24 = Gln, His; R25 = Glu, Asp; R27 = D- or L-Nle, D- or L-Ile, D- or L-Leu, D- or L-Met, D- or L-Val; R28 = Asn, Ser, D-Ala; R34 = Arg, Ser, Ala; R38 = Gln, Arg, Ser; R39 = Arg, Gly; R40 = Ala, Ser, Arg, bond; R41 = Arg, Phe, Lys, bond; R42 = Val, Phe, Ala, Gln, Gly, Ile, Leu, Lys, Pro, bond; R43 = Asn, Arg, bond; R44 = Leu, bond], were prepared [D-HArg(Et2)2]1-29(NH2)-hGRF was prepared via solid-phase synthesis using a benzhydrylaminopolystyrene-1% divinylbenzene resin.


IT 110781-88-9P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as growth hormone releasing factor analog)  
 RN 110781-88-9 CAPLUS  
 CN Somatoliberin (human pancreatic islet), 2-D-arginine-27-L-norleucine-29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)

NTE modified


SEQ 1 YRDAIFTNSY RKVLGQLSAR KLLQDIXSR

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 3-A



PAGE 3-B

—NH2

L23 ANSWER 45 OF 49 CAPLUS COPYRIGHT 2007 ACS on STN  
 ACCESSION NUMBER: 1987-691 CAPLUS Full-text  
 DOCUMENT NUMBER: 106-691

TITLE: Comparative structural requirements of thirty GRF analogs for interaction with GRF and VIP receptors and coupling to adenylate cyclase in rat adenopituitary, liver and pancreas

AUTHOR(S): Robberecht, Patrick; Waelbroeck, Magali; Coy, David; De Neef, Philippe; Camus, Jean Claude; Christophe, Jean


CORPORATE SOURCE: Med. Sch., Univ. Libre Bruxelles, Brussels, Belg.  
 SOURCE: Peptides (New York, NY, United States) (1986), 7(Suppl. 1), 53-9

CODEN: PPTDD5; ISSN: 0196-9781

DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB The ability of (1-29)-human growth hormone-releasing factor-NH2 [(1-29)-GRF-NH2] [86168-78-7] and 30 analogs to stimulate adenylate cyclase [9012-42-4] activity was investigated in membranes from adenopituitary, liver, and pancreas of rat. In adenopituitary membranes, GRF and GRF analogs interacted with specific GRF receptors, whereas in liver and pancreatic membranes, they interacted with VIP [37221-79-7] receptors. The C-terminal moiety of GRF was responsible for GRF receptor recognition, since the hybrid analog [(1-9)-(His1,D-Ala2)-GRF]-(10-28)-VIP [105605-65-0] stimulated pituitary adenylate cyclase through the occupancy of VIP receptors only. When GRF of VIP





L23 ANSWER 46 OF 49 CAPLUS COPYRIGHT 2007 ACS on STM  
ACCESSION NUMBER: 1986:565181 CAPLUS Full-text

DOCUMENT NUMBER:  
105:165181

TITLE:  
Strategies in the design of synthetic agonists and antagonists of growth hormone releasing factor

AUTHOR (S):  
Coy, David H.; Murphy, William A.; Lance, Valentine A.; Helman, Mark L.

CORPORATE SOURCE:  
Sch. Med., Tulane Univ., New Orleans, LA, 70112, USA

SOURCE:  
Peptides (New York, NY, United States) (1986  
, 7(Suppl. 1), 49-52

CODEN: PPTDDS; ISSN: 0196-9781

DOCUMENT TYPE:  
Journal

English



AB Analog studies on the sequence-related 1-12 region of growth hormone-releasing factor (1-29) amide [GRF(1-29)NH<sub>2</sub>] [86168-78-7] carried out. Replacement of each of the 11 amino acids by its D-isomer in turn gave a total of 5 analogs exhibiting increases in potency. Other analogs containing multiple D-amino acid replacements were also examined and potent, for instance: D-Tyr-1, D-Ala-2 [104670-92-0], 2630; His-1, D-Ala-2 [104670-93-1], 3440; Ac-His-1, D-Ala-2 [93942-90-6], 1574; D-Ala-2, Nle-27 [101366-31-8], 1840; D-Ala-2, D-Asn-8, Nle-27 [101383-48-7], 1580; D-Ala-2, D-Asp-3, D-Asn-8, Nle-27 [104670-94-2], 2000; D-Asp-3, D-Asn-8, Nle-27 [101366-32-9], 3810 [GRF(1-29) = 100%]. These results with D-isomers may reflect the presence of reverse turns (β-bends) in this region of GRF. Indeed, the qual. predictive method of Chou and Fasman supports this theory and indicates reverse turns in the 1-5 and 6-10 sequences. In introducing even more rigidity into the N-terminal region via disulfide bond formation between positions normally containing aromatic amino acids, none of the bridged peptides displayed biol. activity which suggests that chain folding does not produce any proximity among N-terminal residues. Since position 2 was extremely sensitive to both conformational and side-chain alterations, this observation was extended to analogs containing sarcosine and proline, both of which were also inactive on growth hormone (GH) [9002-72-6] release at the doses tested. Previously, 2 position 2 analogs, Ac-D-Tyr-1, D-Arg-2 [104670-93-3]- and [Ac-Tyr-1, D-Phe-2]-GRF(1-29)NH<sub>2</sub> [93965-89-0] were found to be competitive antagonists of GRF adenylate cyclase activity in various tissues but were not able to block the in vivo or in vitro GH-releasing activity of GRF. Likewise, none of the new position 2 peptides were able to block the GH-releasing activity of GRF indicating that their loss of biol. activity is caused by reduced receptor affinities.

IT 104670-95-3  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(growth hormone releasing activity of, structure in relation to)

RN 104670-95-3 CAPLUS  
CN Somatoliberin (human pancreatic islet), 1-(N-acetyl-D-tyrosine)-2-D-arginine-29-L-argininamide-30-de-L-glutamine-31-de-L-glutamine-32-deglycine-33-de-L-glutamic acid-34-de-L-serine-35-de-L-asparagine-36-de-L-glutamine-37-de-L-glutamic acid-38-de-L-arginine-39-deglycine-40-de-L-alanine-41-de-L-arginine-42-de-L-alanine-43-de-L-arginine-44-de-L-leucinamide- (9CI) (CA INDEX NAME)

NTE modified

SEQ 1 YRDIAFTNSY RKVLGQLSAR KLIQDIMSR







NTE modified

SEQ 1 YRDAIFTNSY R KVLGQLSAR KLLQDIMSR


PAGE 1-A




PAGE 1-B




PAGE 2-A



PAGE 2-B



PAGE 2-C















FILE 'HOME' ENTERED AT 12:24:16 ON 20 SEP 2007

SEARCH HISTORY

=> d his nofile

(FILE 'HOME' ENTERED AT 11:58:35 ON 20 SEP 2007)

FILE 'CAPLUS' ENTERED AT 11:58:46 ON 20 SEP 2007

E US2006-566776/APPS

SEA ABB=ON US2006-566776/AP

D SCAN

5 SEA ABB=ON SCHALLY A?/AU

0 SEA ABB=ON VARGA J2/AU

SEA ABB=ON VARGA J:/AO  
SEA ABB=ON ZABANDT M2/AII

1 SEA ABB=ON CAT R2/ALL  
2 SEA ABB=ON CAT R2/ALL

SEA ABB=01  
SET. RN 1.1

FILE 'REGISTRY' ENTERED AT 11:59:50 ON 20 SEP 2007

L6

FILE "C:\MSOFT\ENTERED AT 11:39:30 AM 20 SEP 2007"

116 SEA ABB-ON (845715-10-8/BI OR 845715-11-9/BI OR 845715-12-0/BI OR  
OR 845715-13-1/BI OR 845715-14-2/BI OR 845715-15-3/BI OR  
845715-16-4/BI OR 845715-17-5/BI OR 845715-18-6/BI OR 845715-19-7/BI OR 845715-20-0/BI OR 845715-21-1/BI OR 845715-22-2/BI OR  
845715-23-3/BI OR 845715-24-4/BI OR 845715-25-5/BI OR 845715-26-6/BI OR 845715-27-7/BI OR 845715-28-8/BI OR 845715-29-9/BI OR  
845715-30-2/BI OR 845715-31-3/BI OR 845715-32-4/BI OR 845715-33-5/BI OR 845715-34-6/BI OR 845715-35-7/BI OR 845715-36-8/BI OR  
845715-37-9/BI OR 845715-38-0/BI OR 845715-39-1/BI OR 845715-40-4/BI OR 845715-41-5/BI OR 845715-42-6/BI OR 845715-43-7/BI OR  
845715-44-8/BI OR 845715-45-9/BI OR 845715-46-0/BI OR 845715-47-1/BI OR 845715-52-8/BI OR 845715-53-9/BI OR 845715-54-0/BI OR  
845715-55-1/BI OR 845715-56-2/BI OR 845715-57-3/BI OR 845715-58-4/BI OR 845715-59-5/BI OR 845715-60-8/BI OR 845715-61-9/BI OR  
845715-62-0/BI OR 845715-63-1/BI OR 845715-72-2/BI OR 845715-73-3/BI OR 845715-74-4/BI OR 845715-75-5/BI OR 845715-76-6/BI OR  
845715-77-7/BI OR 845715-78-8/BI OR 845715-79-9/BI OR 845715-80-2/BI OR 845715-81-3/BI OR 845715-82-4/BI OR 845715-83-5/BI OR  
845715-84-6/BI OR 845715-85-7/BI OR 845715-86-8/BI OR 845715-87-9/BI OR 845715-88-0/BI OR 845715-89-1/BI OR 845715-90-4/BI OR  
845715-91-5/BI OR 845715-92-6/BI OR 845715-93-7/BI OR 845715-94-8/BI OR 845715-95-9/BI OR 845715-96-0/BI OR 845715-97-1/BI OR  
845715-98-2/BI OR 845715-99-3/BI OR 845716-00-9/BI OR 845716-01-0/BI OR 845716-02-1/BI OR 845716-03-2/BI OR 845716-04-3/BI OR  
845716-05-4/BI OR 845716-06-5/BI OR 845716-07-6/BI OR 845716-08-7/BI OR 845716-09-8/BI OR 845716-10-1/BI OR 845716-11-2/BI OR  
845716-12-3/BI OR 845716-13-4/BI OR 845716-14-5/BI OR 845716-15-6/BI OR 845716-16-7/BI OR 845716-17-8/BI OR 845716-18-9/BI OR  
845716-19-0/BI OR 845716-20-3/BI OR 845716-21-4/BI OR 845716-22-5/BI OR 845716-23-6/BI OR 845716-24-7/BI OR 845716-25-8/BI OR  
845716-26-9/BI OR 845716-27-0/BI OR 845716-28-1/BI OR 845716-29-2/BI OR 845716-30-5/BI OR 845716-31-6/BI OR 845716-32-7/BI OR  
845716-33-8/BI OR 845716-

FILE 'LREGISTRY' ENTERED AT 11:59:57 ON 20 SEP 2007

FILE  
L7  
LREGISTRATION ENMIRK AD 11:39:37 ON 20 SEP 2007  
0 SEA ABBS-ON [YH] [R'CIT'] [DA] [IV] [FY] [NAL] [T] [N'CIT'] [QSTA] [ABU] [AIB'] ..  
.. [K'ORN'] [HAR'] [CIT'] [N'LE'] [AIV] [GA] [ABU] [AIB'] [N'LE'] [Q'CIT'] [H] [QR] [A] [AB  
U'] [HR] [CIT'] [K'ORN'] [CIT'] [LA] [AIV] [LQDI] [ML] [N'LE'] [ABU] [R'] [R' HAR'] [SND  
A] [ABU] [CIT'] [CIT'] /\$OSP  
18  
0 SEA ABBS-ON [YH] [R'CIT'] [DA] [IV] [FY] [NAL] [T] [N'CIT'] [QSTA] [ABU] [AIB'] ..  
.. [K'ORN'] [HAR'] [CIT'] [N'LE'] [AIV] [GA] [ABU] [AIB'] [N'LE'] [Q'CIT'] [H] [QR] [A] [AB  
U'] [HR] [CIT'] [K'ORN'] [CIT'] [LA] [AIV] [LQDI] [ML] [N'LE'] [ABU] [R'] [R' HAR'] [S  
NDA] [ABU] [CIT'] [CIT'] /\$OSP

L8  
 0 SBA ABBSN [YH] [R 'CIT'] /SOSP  
 ...[K'ORN' 'HAB' 'CIT' 'NLE' 'AVLGA' 'ABU' 'ATB' 'NLE' 'Q' 'CIT' 'H] [QRLSIA'  
 ...[H'R 'CIT'] [K'ORN' 'CIT'] [LA' AIB' ] LQDI [ML 'NLE' 'ABU' R'] [R' HAR' S  
 NDA' ABU' 'CIT' ] /SOSP

L9 FILE 'REGISTRY' ENTERED AT 12:08:37 ON 20 SEP 2007  
 227 SEA ABB=ON [YH][R'CIT']DA[IV][FY'NAL']TIN'CIT'QSTA'ABU''AIB'].  
 ..[K'ORN'HAR''CIT'NLE'A]VL[CA'ABU'AIB'NLE'Q'CIT'H][OR]LS[A'  
 ABU']HR'CIT']K'ORN'CIT']LA'AIB']LQDI[ML'NLE'ABU'R][R'HAR'S  
 NDA'ABU'CIT']]/SQSP  
 SAVE TEMP L9 HA776SEQ1/A  
  
 FILE 'STNGUIDE' ENTERED AT 12:09:18 ON 20 SEP 2007  
  
 L10 FILE 'LREGISTRY' ENTERED AT 12:10:34 ON 20 SEP 2007  
 0 SEA ABB=ON YRDA[IV]FTHYH'ORN'VL'ABU'[OR]LS[A'ABU']H'ORN'[LA'A  
 IB']LQDI'NLE'R'HAR'/SQSP  
 SAVE TEMP L11 HA776SEQ2/A  
 D LC 1-5  
 L12 111 SEA ABB=ON L6 AND L9  
 L13 5 SEA ABB=ON L6 NOT L9  
 D SCAN  
  
 L11 FILE 'REGISTRY' ENTERED AT 12:15:46 ON 20 SEP 2007  
 5 SEA ABB=ON YRDA[IV]FTHYH'ORN'VL'ABU'[OR]LS[A'ABU']H'ORN'[LA'A  
 IB']LQDI'NLE'R'HAR'/SQSP  
 SAVE TEMP L11 HA776SEQ2/A  
 D LC 1-5  
 L12 111 SEA ABB=ON L6 AND L9  
 L13 5 SEA ABB=ON L6 NOT L9  
 D SCAN  
  
 L14 FILE 'CAPLUS' ENTERED AT 12:17:40 ON 20 SEP 2007  
 73 SEA ABB=ON L9  
 3 SEA ABB=ON L11  
 L15 49 SEA ABB=ON L14 AND (PY<2003 OR AY<2003 OR PRY<2003)  
 L16  
  
 L17 FILE 'CAPLUS' ENTERED AT 12:18:46 ON 20 SEP 2007  
 49 SEA ABB=ON (L1 AND L14) OR (L2 AND L3 AND L4 AND L5) OR (L2  
 OR L3 OR L4 OR L5) AND L14)  
 L18 49 SEA ABB=ON (L1 AND L14) OR ((L2 OR L3 OR L4 OR L5) AND L14)  
 L19 3 SEA ABB=ON (L1 AND L14) OR (L2 AND L3 AND L4 AND L5 AND L14)  
 L20 48 SEA ABB=ON L14 AND ((L2 AND (L3 OR L4 OR L5)) OR (L3 AND (L4  
 OR L5)) OR (L4 AND L5))  
 D QUE L19  
 D IBIB ABS HITSEQ L19 1-3  
  
 FILE 'REGISTRY' ENTERED AT 12:21:40 ON 20 SEP 2007  
 D QUE L11  
  
 L21 FILE 'CAPLUS' ENTERED AT 12:21:54 ON 20 SEP 2007  
 D QUE L15  
 2 SEA ABB=ON L15 NOT L19  
 L22 D IBIB ABS HITSEQ L21 1-2  
 1 SEA ABB=ON L15 AND L19  
 D SCAN T1  
  
 FILE 'REGISTRY' ENTERED AT 12:22:32 ON 20 SEP 2007  
 D QUE L9  
  
 L23 FILE 'CAPLUS' ENTERED AT 12:22:37 ON 20 SEP 2007  
 D QUE L16  
 49 SEA ABB=ON L16 NOT (L19 OR L15)  
 SEL HIT RN L23  
 D COST  
 D IBIB ABS HITSEQ L23 1-49  
  
 FILE 'HOME' ENTERED AT 12:24:16 ON 20 SEP 2007